2023 年终盘点大纲公布！13大瘤种最新进展，一文速览！

（以下按瘤肿拼音排序）

局晚期鼻咽癌治疗进展
1.     CONTINUUM研究（2023 ASCO LBA6002）—一项多中心、III期、随机对照CONTINUUM研究: 信迪利单抗全程联合诱导化疗和同步放化疗（IC-CCRT）与IC-CCRT在局部区域晚期鼻咽癌（LANPC）的疗效比

2.     NCT0332159（2023 ASCO LBA6000）—N2-3期鼻咽癌同步放化疗后辅助化疗GP对比PF方案：一项多中心、开放、前瞻性、随机对照III期研究

3.     NCT02460887（2023 ASCO LBA6001）—在局晚期鼻咽癌中比较IC+单放与CCRT：一项开放、非劣、随机对照III期研究

4.     NCT05503914（2023 ASCO 6049）—低剂量分割放疗（LDFRT）联合新辅助化疗（NACT）治疗T3-4期鼻咽癌：一项II期随机对照试验

5.     NCT05397769（2023 ESMO 920P）—Envafolimab联合放化疗治疗局晚期鼻咽癌的前瞻性、单臂、II期临床研究

6.     ChiCTR2200057343(2023 ESMO 929P)—帕博利珠单抗联合白蛋白紫杉醇和铂类一线治疗鼻腔和鼻旁窦复发转移性头颈部鳞状细胞癌

7.     一项探索调强放疗（IMRT）vs. IMRT+碳离子束放疗（CIRT）治疗非转移性鼻咽癌患者的生存结果和毒性的倾向评分匹配分析（2023 ESMO 915P）

8.     通过改变鼻咽癌放疗剂量减少辐射引起的颞叶损伤（2023 ESMO 916P）

9.     Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. （The Lancet. February 23, 2023.） 

局部晚期复发鼻咽癌调强放疗中超分割与常规分割的比较：一项多中心、随机、开放标签的3期试验

 
局晚期鼻咽癌治疗进展
1.     JUPITER-02研究的最终总生存期分析（2023 ASCO 6009）—特瑞普利单抗对比安慰剂联合GP作为复发或转移性鼻咽癌一线治疗的III期研究

2.     NCT04872582（2023 ASCO 6031）—信迪利单抗联合贝伐珠单抗治疗铂类化疗失败后转移性鼻咽癌的疗效和安全性：一项开放II期研

3.     NEOSPACE研究（2023 ASCO 6010）—对于IV期鼻咽癌，帕博利珠单抗+吉西他滨+顺铂新辅助治疗随后同步帕博利珠单抗+放化疗和帕博利珠单抗维持治疗

4.     ChiECRCT20210147（2023 ASCO e18011）—化疗联合安罗替尼、特瑞普利单抗和立体定向放疗治疗寡转移鼻咽癌的前瞻性、多中心二期临床研究

5.     一项探索TGF-βRI抑制剂GFH018联合特瑞普利单抗治疗复发/转移性鼻咽癌的1b/II期临床研究（2023 ASCO 6026）

6.     NCT05126719（2023 ESMO 860MO）—MRG 003：一种用于治疗复发/转移性鼻咽癌的新型靶向EGFR抗体药物偶联物（ADC）

7.     TORAL研究（2023 ESMO 912P）—特瑞普利单抗联合安罗替尼治疗经治的复发或转移性鼻咽癌：一项II期单臂研究的中期分析

8.     NCT04156698(2023 ESMO 934P)—卡瑞利珠单抗联合多西他赛、顺铂和卡培他滨用于晚期下咽癌诱导治疗的抗肿瘤活性和安全性
 
鼻咽癌外科治疗进展
《鼻咽癌外科治疗专家共识》

Session1：儿童实体瘤研究进展
 
  Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial 对比VDC/IE（长春新碱、阿霉素、环磷酰胺与异环磷酰胺和依托泊苷交替使用）和VIDE方案（长春新碱、阿霉素、异环磷酰胺和依托泊苷）的开放随机III期临床研究（EE2012）（Lancet）

  阿帕替尼联合伊立替康和替莫唑胺（AIT）方案进一步提高复发难治神经母细胞瘤患者的疗效（2023 SIOP，Oral）

  儿童梭形细胞/硬化型横纹肌肉瘤（SSRMS）的分子和临床特征：一项来自中国儿童肿瘤精准诊疗协作组的精准诊疗报告（2023 SIOP，Oral）

   A phase II study to explore the efficacy and safety of FCN-159 in recurrent or progressive pediatric low-grade glioma (pLGG) with MAPK pathway-activated一项探讨FCN-159治疗MAPK通路激活的复发或进行性儿童低级别胶质瘤（pLGG）的疗效和安全性的Ⅱ期研究（2023 ESMO，499O）

 A phase I dose-expansion cohort of SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3 /colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients (pts) with recurrent meningioma血管内皮生长因子受体（VEGFR）1-3/集落刺激因子1受体（CSF1R）抑制剂SYHA1813在复发性脑膜瘤患者（pts）中的I期剂量扩大队列研究（2023 ESMO，506MO）

l A Multicenter, Open-label, Single-arm Phase 1/2 Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1FCN-159在儿童NF1患者中的1/2期研究结果（2023 ASCO，poster 10023）
 
Session2：儿童血液肿瘤研究进展
 
急性髓系白血病（AML）
基础研究
  A DNA Methylation Signature Predicts Clinical Outcome in Pediatric AML Patients. （ASH2023, Abs: 835.）
预测小儿急性髓细胞白血病患者临床结局的DNA甲基化特征

   A Longitudinal Single-Cell Atlas of Treatment Response in Pediatric AML. ASH2023, Abs: 65.
小儿急性髓细胞性白血病治疗反应纵向单细胞图谱
 
预后评估
   Prognostic Role of Molecular MRD Variations during Treatment of Pediatric AML: A Retrospective AIEOP AML2013/01 Study. （ASH2023, Abs: 422.）
小儿急性髓细胞白血病治疗过程中分子 MRD 变异的预后作用： 一项回顾性 AIEOP AML2013/01 研究

   A Randomized Comparison of Liposomal Daunorubicin/Daunorubicin Combined with Low-Dose Cytarabine and Etoposide or High-Dose Cytarabine and Fludarabine in Induction Treatment of Pediatric AML Using MRD-Based Risk Stratification in the NOPHO-DBH AML 2012 Protocol. （ASH2023, Abs: 831.）
随机比较脂质体多柔比星/多柔比星联合小剂量阿糖胞苷和依托泊苷或大剂量阿糖胞苷和氟达拉滨诱导治疗小儿急性髓细胞白血病的疗效，NOPHO-DBH急性髓细胞白血病2012方案采用基于MRD的风险分层

AML新药进展：
  Outcomes for Children with High Risk Acute Myeloid Leukemia on the Myechild 01 International Phase III Clinical Trial. （ASH2023, Abs: 730.）
Myechild 01 国际 III 期临床试验高危急性髓细胞白血病患儿的治疗结果
 
AML传统化疗方案优化：
  Outcomes of Children and Adolescents with Acute Myeloid Leukemia Given a Low-Versus Standard-Dose Chemotherapy Regimen for Remission Induction (CALSIII-AML18): A Multicenter, Phase 3, Randomized, Noninferiority Trial. （ASH2023, Abs: 729.）
采用低剂量化疗方案与标准剂量化疗方案进行诱导缓解的急性髓细胞白血病儿童和青少年患者的疗效（CALSIII-AML18）： 一项多中心、3 期、随机、非劣效试验。

  Final Results of the AIEOP (Associazione Italiana Ematologia/Oncologia Pediatrica) AML 2013 Prospective Randomized Trial in Childhood Acute Myeloid Leukemia (AML). （ASH2023, Abs: 728.
儿童急性髓细胞白血病（AML）AIEOP（意大利肿瘤/儿科协会）AML 2013 前瞻性随机试验的最终结果。
 
AML CAR-T治疗：
  CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial. ASH2023, Abs: 771.
CD33 CAR T 细胞（CD33CART）用于治疗儿童和青年复发性/难治性急性髓细胞白血病： I/II期多中心试验的剂量扩展结果
 
AML 移植治疗：
  Impact of Molecular Risk on Efficacy of Blood and Marrow Transplantation for Pediatric Acute Myeloid Leukemia: A Report from the Children’s Oncology Group. （ASH2023, Abs: 655.）
分子风险对小儿急性髓细胞白血病血液和骨髓移植疗效的影响： 儿童肿瘤学组报告
 
急性淋巴细胞白血病（ALL）
基础研究：
Single-Cell Genomics Details the Maturation Block in BCP-ALL and Identifies Therapeutic Vulnerabilities in DUX4-Rearranged Cases. （ASH2023, Abs: 842.）
单细胞基因组学详解 BCP-ALL 成熟障碍并确定 DUX4 重排病例的治疗弱点

ALL新药及治疗进展：
 Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab – Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017. （ASH2023, Abs: 825.）
首次完全缓解的高危B细胞ALL儿科患者可能受益于毒性较低的贝林妥欧单抗免疫疗法--随机对照3期试验AIEOP-BFM ALL 2017的结果
 
 Outcome of Infants Treated on Total Therapy for Infants with Acute Lymphoblastic Leukemia I: Results from a Non-Randomized Multi-Center Study. （ASH2023, Abs: 823.）
对急性淋巴细胞白血病 I 期婴儿进行全面治疗的结果： 一项非随机多中心研究的结果

  Preliminary Safety and Efficacy of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia: Selclax. （ASH2023, Abs: 56.）
维奈克拉和塞利尼索联合化疗治疗复发性或难治性急性髓细胞白血病儿童和年轻成人患者的初步安全性和有效性
 
  Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia. N Engl J Med. 2023;388(17):1572-1581.
在婴儿淋巴细胞白血病化疗中加入贝林妥欧单抗的研究
 
ALL传统化疗方案优化：
  Association between High Antimetabolite Dose Intensity during Maintenance, Toxicities and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): COG-AALL03N1 Report. （ASH2023, Abs: 521.）
急性淋巴细胞白血病（ALL）患儿维持治疗期间高抗代谢物剂量强度、毒性和复发风险之间的关联： COG-AALL03N1 报告

  ATM Germline Pathogenic Variants Affect Treatment Outcomes in Children with Acute Lymphoblastic Leukemia/Lymphoma and Ataxia Telangiectasia. （ASH2023, Abs: 520.）
ATM 基因致病变异影响急性淋巴细胞白血病/淋巴瘤和共济失调性特发性白血病患儿的治疗效果

  Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. （Blood. 2023 Feb 16;141(7):704712.doi:10.1182/blood.2022016923.）
重组欧文氏天冬酰胺酶（JZP458）治疗急性淋巴细胞白血病：2/3 期 AALL1931 研究结果

  Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse. DOI: 10.1200/JCO.22.02200 Journal of Clinical Oncology 41, no. 25 (September 01, 2023) 4118-4129. Published online May 31, 2023.
儿童肿瘤学组 AALL1331： 首次复发的低风险 B 细胞 ALL 儿童、青少年和青年患者的贝林妥欧单抗 III 期试验。

  Risk-Adjusted Therapies Yield Equivalent Outcomes for Adolescents and Young Adults (AYAs) Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) on Children’s Oncology Group (COG) Studies AALL0434 and AALL123. https://ash.confex.com/ash/2023/webprogram/Paper190141.html
儿童肿瘤学组 (COG) AALL0434 和 AALL123 研究中新诊断为 T 细胞急性淋巴细胞白血病 (T-ALL) 的青少年和年轻成人 (AYAs) 采用风险调整疗法可获得同等疗效

  A Nationwide Clinical Trial ALL-B12: An Optimized Therapy for Pediatric B-Precursor Acute Lymphoblastic Leukemia with Excellent Overall Survival and Minimal Non-Relapse Mortality: A Report from the Japan Children Cancer Group. https://ash.confex.com/ash/2023/webprogram/Paper182464.html
一项全国范围的临床试验 ALL-B12：小儿 B 前体急性淋巴细胞白血病的优化疗法，总生存期极佳，非复发死亡率极低： 日本儿童癌症小组报告

  association between High Antimetabolite Dose Intensity during Maintenance, Toxicities and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): COG-AALL03N1 Report. https://ash.confex.com/ash/2023/webprogram/Paper187197.html
急性淋巴细胞白血病（ALL）患儿维持治疗期间高抗代谢物剂量强度、毒性和复发风险之间的关联： COG-AALL03N1 报告
 
T-ALL：
  Risk-Adjusted Therapies Yield Equivalent Outcomes for Adolescents and Young Adults (AYAs) Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) on Children’s Oncology Group (COG) Studies AALL0434 and AALL1231. （ASH2023, Abs: 517.）
儿童肿瘤学组 (COG) AALL0434 和 AALL1231 研究中新诊断为 T 细胞急性淋巴细胞白血病 (T-ALL) 的青少年和年轻成人 (AYAs) 采用风险调整疗法可获得同等疗效

  STAG2/LMO2 Gamma-Delta (γδ) T-ALL: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young. （ASH2023, Abs: 845.）
TAG2/LMO2 Gamma-Delta (γδ) T-ALL：非常年轻的 T-ALL 极高风险群体的鉴定和特征描述

  Clonal Evolution Dissection Reveals High MSI2 Level Promotes Chemo-Resistance in T-Cell Acute Lymphoblastic Leukemia. （ASH2023, Abs: 846.）
克隆进化剖析揭示高MSI2水平促进T细胞急性淋巴细胞白血病的化疗耐药性

  The Transcription Factors NFATc1 and NFATc2 Control Glucocorticoid Resistance in Pediatric T-Cell Acute Lymphoblastic Leukemia. （ASH2023, Abs: 420.）
转录因子 NFATc1 和 NFATc2 控制小儿 T 细胞急性淋巴细胞白血病的糖皮质激素抵抗
 
CAR-T研究进展：
  Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia. （Nat Med. 2023;29(7):1700-1709.）
与白血病患儿 CD19 CAR-T 细胞持续存在相关的转录特征

  Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia. （N Engl J Med. 2023;389(10):899-910.）
基因编辑的 CAR7 T 细胞治疗复发 T 细胞急性淋巴细胞白血病

  Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. （J Clin Oncol. 2023 Mar 20;41(9):1664-1669.doi: 10.1200/JCO.22.00642.）
LIANA试验中Tisagenlecleucel治疗儿童和年轻成人复发性/难治性急性淋巴细胞白血病患者的3年最新进展

  Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial. （J Clin Oncol. 2023 Mar 20;41(9):1670-1683. doi: 10.1200/JCO.22.01214.）
在儿童 B 细胞急性淋巴细胞白血病中联合应用 CD19 和 CD22 引导的嵌合抗原受体 T 细胞疗法： 单臂、多中心、II 期试验
 
ALL移植进展：
  Outcome of Children with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with Hypodiploidy or BCR-ABL1 Fusion Given Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Results from the Prospective Forum Study. （ASH2023, Abs: 1050.）
伴有低二倍体或 BCR-ABL1 融合的 B 细胞前体急性淋巴细胞白血病 (BCP-ALL) 患儿接受异基因造血干细胞移植 (HSCT) 的结果

慢性粒细胞白血病（CML）
   Is the Eutos Long Term Survival (ELTS) Score a Useful Marker to Predict Outcome in Children with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)? the Experience of the International Registry of Childhood CML. （ASH2023, Abs: 448.）
Eutos 长期生存（ELTS）评分是否是预测新诊断为慢性期（CP）慢性髓性白血病（CML）患儿预后的有用指标？

   Preliminary results from the first-in-child phase II trial (ITCC-054/COG-AAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML). （2023ASCO, abstr 10017.）
博舒替尼治疗新诊断（ND）慢性髓细胞白血病（CML）儿童患者的首次儿童II期试验（ITCC-054/COG-AAML1921）的初步结果
 
淋巴瘤
   Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826. （ASH2023, Abs: 610.）
  Nivolumab-AVD 与 Brentuximab Vedotin-AVD 相比在小儿晚期 (AS) 经典霍奇金淋巴瘤 (cHL) 中的无进展生存期 (PFS) 和毒性，SWOG S1826 的结果

   Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults. （Blood. 2023;141(17):2075-2084.）
Nivolumab和brentuximab vedotin联合或不联合苯达莫司汀治疗儿童、青少年和年轻成人的R/R霍奇金淋巴瘤

   SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). （2023ASCO, abstr LBA4.）
SWOG S1826：一项对晚期（AS）典型霍奇金淋巴瘤（HL）进行的nivolumab（N）-AVD与brentuximab vedotin（BV）-AVD的随机研究
 
骨髓增殖性肿瘤
l Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: A Report from the Children’s Oncology Group （ASH2023, Abs: 74.）
异位MEK抑制剂曲美替尼对复发和难治性幼年骨髓单核细胞白血病的疗效： 儿童肿瘤学组报告
 
中国好声音：
   Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study. （J Clin Oncol. 2023 Aug 2:JCO2202836. doi: 10.1200/JCO.22.02836. ）中国儿童白血病协作组（北京儿童医院血液病中心郑胡镛教授作为通讯作者）以高三尖杉酯碱为基础的诱导治疗方案显著提高了中国儿童AML患者的缓解率和生存率

   Clonal Evolution Dissection Reveals High MSI2 Level Promotes Chemo-resistance in T-cell Acute Lymphoblastic Leukemia. （Blood. 2023 Oct 6:blood.2023020490. doi: 10.1182/blood.2023020490. Epub ahead of print. PMID: 37801708. ）血研所竺晓凡教授等首次揭示急性T细胞淋巴细胞白血病克隆演化模式并发现其耐药新机制。

   Rui-Juan Sun (China)，P003 COMPARISONS OF SAFETY AND EFFICACY OF ALLO-HSCT AFTER CAR T-CELL OR CHEMOTHERAPY-BASED COMPLETE REMISSION IN PEDIATRIC T-ALL. https://ebmt2023.abstractserver.com/program/#/details/presentations/1379 儿童T-ALL CAR-T或化疗完全缓解后行ASCT的安全性和有效性比较

   李晓兰, 刘立鹏, 刘芳, 等. 贝林妥欧单抗治疗儿童复发/难治急性淋巴细胞白血病的安全性及近期疗效分析[J]. （中国当代儿科杂志, 2023, 25(4): 374.）

Session1：围术期NSCLC研究进展
新辅助/辅助治疗：
1. Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC). (2023 ASCO)
ADAURA研究：切除EGFR突变ⅠB-ⅢA期非小细胞肺癌 (NSCLC) 患者中奥希替尼辅助治疗的OS分析

2. Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression. (2023 ESMO)
CheckMate 816：纳武利尤单抗联合化疗新辅助治疗基于PD-L1表达的3年结果

3.  ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC). (2023 ESMO)

ALINA研究：在早期ALK+非小细胞肺癌患者中辅助阿来替尼对比化疗的疗效和安全性

4. Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial. (2023 ESMO)
可切除NSCLC患者新辅助治疗ctDNA清除率和病理缓解之间的关联

5. Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer. (2023 ESMO)
立体定向放射治疗序贯免疫化疗新辅助治疗可切除非小细胞肺癌

6. Surgery after Neoadjuvant Immuno-Chemoradiotherapy in (Borderline) Resectable NSCLC: Results from the INCREASE Trial. (2023 WCLC)
INCREASE试验结果：（临界）可切除NSCLC患者在新辅助免疫联合放化疗后进行手术

7. A Novel Multiparameter Biomarker of Pathological Response for NSCLC Receiving Neoadjuvant Immunotherapy: A Real-world Study. (2023 WCLC)
NSCLC新辅助免疫治疗病理反应的新型多参数生物标志物:一项真实世界研究

8. Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial. (2023 ESMO)
CheckMate 816研究探索性分析：新辅助纳武利尤单抗联合伊匹木单抗对比化疗

9. NEOIPOWER: Icotinib plus Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-IIIB EGFR-mutant Lung Adenocarcinoma（2023 WCLC）
NEOIPOWER研究：埃克替尼联合化疗作为可切除II-IIIB期EGFR突变肺腺癌的新辅助治疗

10. NEOEAST: A Phase II Study of Ensartinib as Neoadjuvant Therapy for Stage II-IIIB ALK-rearranged Non-small Cell Lung Cancer（2023 WCLC）
NEOEAST研究：恩沙替尼新辅助治疗II-IIIB期ALK重排非小细胞肺癌的II期研究（2023 WCLC）

围术期治疗：
1.  CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II-IIIb NSCLC (2023 ESMO)
III期CheckMate 77T研究，比较新辅助纳武利尤单抗联合化疗对比新辅助安慰剂联合化疗，然后手术和辅助纳武利尤单抗或安慰剂治疗既往未经治疗的可切除的II-IIIb期NSCLC 

2.  Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study.（2023 ASCO）
III期NEOTORCH研究的中期EFS分析:可切除的II/III期NSCLC患者围手术期特瑞普利单抗+化疗与化疗的比较

3.  Perioperative Nivolumab and chemotherapy in stage III non-small cell lung cancer（NEJM，doi:10.1056/NEJMoa2215530. Epub 2023 Jun 28.）
NADIM II研究 :III期非小细胞肺癌围手术期采用纳武利尤单抗联合化疗

4. Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial. (2023 ESMO)
RATIONALE-315：替雷利珠单抗+化疗新辅助治疗可切除II-IIIA期NSCLC

5. Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable EGFR-mutated NSCLC (AEGEAN)
AEGEAN研究：新辅助度伐利尤单抗+化疗，辅助度伐利尤单抗治疗可切除NSCLC

6. Surgical Outcomes with Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC (AEGEAN). (2023 WCLC)
AEGEAN研究：新辅助度伐利尤单抗+化疗，术后辅助度伐利尤单抗治疗可切除NSCLC的手术结果

7. Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). (2023 ESMO)
KEYNOTE-671：帕博利珠单抗围术期治疗早期NSCLC研究的OS结果
 
SESSION2. 经典突变NSCLC治疗进展
2.1常见突变（EGFR敏感和KRAS突变）NSCLC治疗进展（一线、后线）
EGFR敏感突变
一线治疗：
1. Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer（NSCLC）: EORTC Lung Cancer Group 1613 APPLE trial（2023 ELCC）
奥希替尼对比吉非替尼序贯奥希替尼用于EGFR 突变非小细胞肺癌（NSCLC）患者：EORTC Lung Cancer Group 1613 APPLE 试验结果

2. Phase II Randomized Study of Osimertinib（OSI）With or Without Local Consolidative Therapy（LCT）for Metastatic EGFR Mutant Non-Small Cell Lung Cancer（NSCLC）: Analysis of Adverse Events（AEs）.（2023 ELCC）
奥希替尼（OSI）±局部巩固治疗（LCT）治疗转移性 EGFR 突变NSCLC 的 II 期随机研究：不良事件（AE）分析

3. Furmonertinib Plus Icotinib for First-Line Treatment of EGFR-mutated Non-Small Cell Lung Cancer （2023 ELCC）
伏美替尼+埃克替尼一线治疗EGFR突变NSCLC的疗效

4. Randomized phase 3 study of first-line AZD3759 （zorifertinib） versus gefitinib or erlotinib in EGFR-mutant （EGFRm+ ） non–small-cell lung cancer （NSCLC） with central nervous system （CNS） metastasis.（2023 ASCO）
AZD3759对比吉非替尼或厄洛替尼用于伴CNS转移EGFR突变NSCLC患者的III期随机对照研究

5. A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non–small-cell lung cancer (NSqNSCLC) harboring EGFR activating mutation (EGFR-NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study.（2023 ASCO）
AGAIN研究 (JCOG1404/WJOG8214L) ：EGFR-TKI单药对比EGFR-TKI联合顺铂+培美曲塞一线治疗EGFR突变晚期非鳞非小细胞肺癌的III期研究

6. Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2) （2023 WCLC）
FLAURA2研究：奥希替尼±含铂化疗一线治疗EGFR突变晚期NSCLC

7. Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial（2023 ESMO）
全球随机对照III期MARIPOSA研究的初步结果：Amivantamab联合Lazertinib对比奥希替尼一线治疗EGFR突变的晚期NSCLC

8. FLAURA2: safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC（2023 ESMO）
FLAURA2：一线（1L）奥希替尼（osi）±化疗（CTx）治疗EGFR突变晚期NSCLC的安全性和中枢神经系统结果

9. Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): a randomized multicenter study（2023 ESMO）
一项随机多中心研究：阿美替尼联合阿帕替尼对比阿美替尼一线治疗EGFR突变局部晚期或转移性NSCLC患者

10.  OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833) （2023 ESMO）
OSIRAM-1：一项多中心、开放标签、随机II期研究，奥希替尼联合雷莫西尤单抗对比奥希替尼用于EGFR突变阳性非鳞状非小细胞肺癌的初始治疗（TORG1833）

11.  A Multi-Centre Open-Label Randomized Phase II Study of Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Metastatic NSCLC (RAMOSE trial interim analysis) （2023 ESMO）
多中心、开放标签、随机化、II期RAMOSE试验中期分析：奥希替尼联合/不联合雷莫西尤单抗一线治疗EGFR突变转移性NSCLC

12. Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC) （2023 ESMO）
pelcitoclax （APG-1252）联合奥希替尼治疗EGFR突变型非小细胞肺癌（NSCLC）的最新研究结果

后线治疗：
1. Bevacizumab plus Atezolizumab and chemotherapy in NSCLC harbouring EGFR mutation previously treated with EGFR Tyrosine Kinase Inhibitor: the BACH-NET study. （2023 ELCC）
BACH-NET研究：贝伐珠单抗+阿替利珠单抗+化疗治疗既往EGFR TKI治疗进展的EGFR 突变NSCLC患者的疗效

2. Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: a single-arm, multicenter, phase II trial.（2023 ELCC）
一线EGFR-TKI进展或局部进展患者中加入安罗替尼治疗NSCLC的结果：一项单臂、多中心、II 期试验

3. Efficacy and safety of 1st generation EGFR TKI retreatment in EGFR mutation positive,T790M negative patients who previously treated with 1st or 2nd generation EGFR TKI and cytotoxic chemotherapy. （2023 ELCC）
第一代 EGFR-TKI再挑战既往接受过第一/二代EGFR-TKI和化疗进展的EGFR突变阳性、T790M 阴性NSCLC患者的疗效和安全性

4. Pralsetinib in acquired RET fusion positive advanced non-small cell lung cancer patients after resistance to EGFR/ALK-TKI: a China multi-center, real-world data（RWD）analysis. （2023 ELCC）
普拉替尼在EGFR/ALK-TKI进展后获得性RET融合阳性晚期NSCLC患者中的疗效：一项在中国开展的多中心真实世界研究

5. Poorer outcomes in EGFR L858R-driven NSCLC treated with osimertinib may be addressed with novel combination of BLU-945 and osimertinib.（2023 AACR）
EGFR L858R NSCLC经奥希替尼疗效不佳患者可采用BLU-945 +奥希替尼联用方案

6. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.（2023 ASCO）

培美曲塞＋铂类±帕博利珠单抗用于TKI耐药后EGFR突变非鳞状NSCLC患者的III期KEYONTE-789研究

7. BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study. （2023 ASCO）
BLU-945±奥希替尼用于经治EGFR突变晚期NSCLC的疗效：I/II期SYMPHONY研究

8. ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors.（2023 WCLC）
ILLUMINATE：度伐利尤单抗联合Tremelimumab和化疗治疗EGFR抑制剂治疗进展的EGFR突变NSCLC的疗效和安全性

9. Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis.（2023 WCLC）
INSIGHT 2研究初步分析：Tepotinib+奥希替尼用于一线奥希替尼治疗后EGFR突变/MET扩增NSCLC患者的疗效

10. Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated Advanced NSCLC After Progression on Osimertinib: MARIPOSA-2, a Phase 3, Global, Randomized, Controlled Trial.（2023 ESMO）
全球随机对照III期MARIPOSA-2研究：Amivantamab＋化疗±Lazertinib对比化疗用于奥希替尼治疗进展后EGFR突变晚期 NSCLC

11. A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04).（2023 ESMO）
一项3期随机研究（ATTLAS, KCSG-LU19-04）：阿替利珠单抗联合贝伐珠单抗和化疗治疗EGFR或ALK突变的非小细胞肺癌患者 

KRAS突变
一线治疗：
1. The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).（2023 ASCO）
II期SCARLET主要终点分析：Sotorasib+卡铂/培美曲塞治疗KRAS G12C突变晚期非鳞状非小细胞肺癌（WJOG 14821 L）

2. KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation.（2023 ESMO）
KRYSTAL-7：adagrasib联合帕博利珠单抗一线治疗KRAS G12C突变的晚期非小细胞肺癌（NSCLC） 患者的疗效和安全性

后线治疗：
1. Patient-reported outcomes from the CodeBreaK 200 phase 3 trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC. （2023 ELCC）
III期试验CodeBreaK 200 患者报告结局：sotorasib对比多西他赛用于KRAS G12C突变 NSCLC患者

2. Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study（2023 AACR）
IBI351 (GFH925) 单药治疗晚期实体瘤的 I 期研究：I 期研究更新结果

3. KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC). （2023 ASCO）
KontRASt-01更新：JDQ-443在KRAS G12C突变实体瘤（包括NSCLC）中的安全性及有效性评估

4. KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors.（2023 WCLC）
KontRASt-01：JDQ443 + TNO155用于KRAS G12C晚期实体瘤的疗效和安全性

5. KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC（2023 WCLC）
KRYSTAL-1：Adagrasib (MRTX849)用于晚期KRAS G12C突变NSCLC患者的2年随访结果

6. CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC. （2023 WCLC）
CodeBreaK 101：Sotorasib联合化疗用于KRAS G12C突变转移性NSCLC的有效性与安全性

7.  lecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors（2023 ESMO）
lecirasib＋JAB-3312用于KRAS p.G12C突变实体瘤患者的疗效
 
SESSION3：罕见突变包含ALK、EGFR 20ins、MET、HER2、ROS1等）NSCLC研究进展（一线、后线）

ALK
术后辅助：
1. efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC).（2023 ESMO LBA2）
ALINA研究：阿来替尼 vs. 化疗辅助治疗早期ALK融合+ NSCLC患者的疗效和安全性

一线：
1. BRIGHTSTAR Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC（2023WCLC OA22.04）
BRIGHTSTAR研究：布格替尼在TKI初治ALK阳性转移性NSCLC中LCT治疗

2. Updated Survival Data in Advanced ALK-rearranged Non-small Cell Lung Cancer Treated with Alectinib and Bevacizumab in the ALEK-B Study（2023 WCLCP2.10-09）
ALEK-B研究：阿来替尼联合贝伐珠单抗治疗晚期ALK重排NSCLC疗效

3. Randomized, Phase 3 Study of Iruplinalkib (WX-0593) vs Crizotinib in Locally Advanced or Metastatic ALK+  NSCLC（2023 WCLC OA03.05）
伊鲁阿克（WX-0593）对照克唑替尼治疗局部晚期或转移性ALK+非小细胞肺癌（NSCLC）的Ⅲ期随机研究

4. Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC in the ALTA-1L and J-ALTA studies.（ASCO 2023. Abstr 9078）
ALTA-1L和J-ALTA研究：布格替尼对ALK TKI初治晚期ALK阳性NSCLC患者的综合疗效和安全性

5.  Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.（ASCO 2023. Abstr 9029）
EML4-ALK融合变体+TP53突变对新一代ALK TKI一线治疗ALK融合阳性NSCLC持续时间的影响

6.  Management of patients with ALK-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trial.（ASCO 2023. Abstr 9063.）
3期CROWN试验中接受脑放疗的ALK阳性晚期非小细胞肺癌患者管理

7. First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data.（2023 ESMO 1371P）
一线阿来替尼与布格替尼在ALK重排晚期转移性非小细胞肺癌中的真实世界数据

8. Updated patient-reported outcomes from the CROWN study: analyses in first-line ALK+ patients with (w) and without (w/o) baseline brain metastases (BMs) and w or w/o central nervous system adverse events (CNS AEs).2023 ESMO 1360P
CROWN研究的患者报告结局更新：在基线伴有或不伴有脑转移（BM）且有或无中枢神经系统不良事件（CNS AE）的ALK+一线患者中进行的分析

后线：
1. Lorlatinib for Previously Treated ALK-positive Advanced NSCLC Updated Efficacy and Safety Data from a Phase 2 Study in China（2023 WCLC MA06.11）
洛拉替尼在经治的ALK阳性晚期NSCLC患者中的疗效与安全性

2.  BrigAlec study – Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019).（2023 ESMO 1369P）
BrigAlec研究：在BrigALK2研究中聚焦布格替尼治疗后阿来替尼的疗效

跨线：
1.  Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study（2023 ESMO 1370P）
一项多中心、开放标签、单臂、II期研究：恩沙替尼在ALK阳性非小细胞肺癌脑转移患者中的疗效和安全性

2. Alectinib activity in ALK+ metastatic non-small cell lung cancer（NSCLC）patients：a national real world analysis (explore ALK, cohort A, GFPC 03-2019).（ASCO 2023. Abstr 9092）
阿来替尼在ALK阳性转移性NSCLC患者中的一项国家真实世界分析（explore ALK，队列A，GFPC 03-2019）

EGFR 20ins
一线：
1.  Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.（Zhou C, Tang K-J, Cho BC, et al. N Engl J Med. 2023 Oct 21. doi: 10.1056/NEJMoa2306441. ）
PAPILLON研究：Amivantamab联合化疗治疗EGFR 20号外显子插入的NSCLC
 
2.  Safety and preliminary efficacy of YK-029A, a novel EGFR TKI, in patients with advanced NSCLC harboring ex20ins, T790M or rare mutations. J Clin Oncol 41, 2023 (Jianchun Duan, et al. suppl 16; abstr 9014)
新型EGFR TKI YK-029 A在携带ex20ins、T790M或罕见突变的晚期NSCLC患者中的安全性和初步疗效

3. A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions. 2023 WCLC. OA03.04.
一项在EGFR 20号外显子插入的晚期NSCLC患者中评价口服、脑渗透性、选择性EGFR抑制剂伏美替尼的Ib期研究

4. Tumor Tissue and Plasma EGFR Exon 20 Insertion Mutation Status in NSCLC Patients Treated with Sunvozertinib，（Mengzhao Wang, et al. 2023WCLC MA14.05）
接受舒沃替尼治疗的NSCLC患者的肿瘤组织和血浆EGFR外显子20插入突变状态

5. Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer. （Zhao, S. et al. Nature communications 14, doi:10.1038/s41467-023-39139-4 (2023).）
抗EGFR抗体JMT101联合奥希替尼治疗EGFR 20号外显子插入阳性非小细胞肺癌的Ib期试验

后线：
1.  Efficacy and safety of sunvozertinib in treatment naïve NSCLC patients with EGFR exon20 insertion mutations. （Xu, Y. et al.Journal of Clinical Oncology 41, 9073-9073, doi:10.1200/JCO.2023.41.16_suppl.9073 (2023).）
舒沃替尼在携带EGFR 20号外显子插入突变的初治NSCLC患者中的疗效和安全性

2.  Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions. （Piotrowska, Z. et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2300152, doi:10.1200/JCO.23.00152 (2023).）
Zipalertinib在携带EGFR 20号外显子插入突变NSCLC患者中的安全性、耐受性和抗肿瘤活性

MET

一线：

1.   A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation. （Lu S, et al. WCLC 2023; OA21.03.）
一项赛沃替尼一线治疗携带MET外显子14突变的局部晚期或转移性NSCLC患者的3b期研究

一线+后线：
1.   Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.（Mazieres J,et al.  JAMA Oncol. 2023;e231962.）
II期VISION非随机临床试验的长期随访：特泊替尼治疗MET14外显子跳突NSCLC患者

2.  Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study. （Paul K,et al. Abstract 9060.）
VISION研究中MET 14外显子跳突NSCLC患者接受特泊替尼治疗的长期结局

3.  Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study. （Leighl N, et al. WCLC 2023; OA21.04.）
CHRYSALIS研究结果：Amivantamab治疗伴有MET外显子14跳突的晚期NSCLC患者

后线：
1.  Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.（Le XN,et al.  2023 ASCO;  Abstract 9070.）
一项病例系列研究：接受特泊替尼联合EGFR TKI治疗的EGFR突变MET改变NSCLC患者

2.  Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib. （Tan DSW,et al. Abstract 9021.）
特泊替尼+奥希替尼治疗奥希替尼一线治疗后出现MET扩增的EGFR突变型NSCLC

3.  Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib.（Yu HA,et al.  2023 ASCO; Abstract 9074.）
奥希替尼一线治疗后EGFR突变NSCLC患者中MET扩增的检测

4.       Tepotinib+Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis.（Kim TM, et al. WCLC 2023; OA21.05.）
INSIGHT 2研究初步分析：特泊替尼+奥希替尼治疗EGFR突变NSCLC奥希替尼一线治疗后出MET扩增

HER2
一线+后线：
1. First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial. （Liu SM, Tu HY, Wei XW, et al. Nat Med. 2023 Aug;29（8）:2079-2086. doi: 10.1038/s41591-023-02461-x. Epub 2023 Jul 24. PMID: 37488286.）
一项以患者为中心的II期试验：吡咯替尼一线治疗晚期HER2突变型非小细胞肺癌

2.  Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02. （Li BT, Planchard D, Goto K, et al. 2023 ESMO. 1321MO.）
来自DESTINY-Lung 01和DESTINY-Lung 02的汇总分析：T-DXd治疗伴和不伴脑转移的HER2突变型转移性NSCLC患者

3. Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic nonesmall cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd). （Smit EF, Felip E, Uprety D, et al. 2023 WCLC. 151P.）
接受T-DXd治疗的HER 2过表达转移性NSCLC患者的基线ctDNA生物标志物分析

4.  Janne P, Goto Y, Kubo T, et al. Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02. 2023 WCLC. MA13.10.
DESTINY-Lung 02的初步结果：德曲妥珠单抗治疗HER2突变转移性非小细胞肺癌患者

ROS1
一线：
1.  Byoung Chul Cho, et al. Repotrectinib in patients with ROS1 fusion-positive non-small cell lung cancer: update from the pivotal phase 1/2 TRIDENT-1 trial. 2023 WCLC Abs OA03.06.
关键性I/II期TRIDENT-1试验的更新：Repotrectinib治疗ROS1融合阳性非小细胞肺癌患者

KRAS G12C
1.  The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).2023 ASCO abstract 9006
SCARLET研究的主要终点分析：一项在KRAS G12C突变的晚期非鳞非小细胞肺癌患者中采用sotorasib联合卡铂-培美曲塞治疗的单臂、II期研究（WJOG 14821 L）
 
SESSION4：驱动基因阴性晚期NSCLC治疗进展（一线、后线）

一线
1. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic nonsmall-cell lung cancer in CheckMate 227. （Brahmer JR, Lee JS, Ciuleanu TE, et al. J Clin Oncol, 2023, 41(6): 1200-1212. DOI:10.1200/JCO.22.01503）
CheckMate 227研究，纳武利尤单抗联合伊匹木单抗对比化疗作为转移性非小细胞肺癌一线治疗的5年生存结局

2. Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.（Jie Wang, Zhijie Wang, Lin Wu, et al. 2023 ASCO Annual Meeting. Abstract #9003.)
CHOICE-01的最终总生存期和生物标志物分析：一项比较特瑞普利单抗与安慰剂联合化疗治疗无EGFR/ALK突变的晚期NSCLC的双盲、随机、III期研究

3. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study，（Gilberto de Castro Jr,et,al.J Clin Oncol. 2023;41(11):1986-1991.Supplements.）
KEYNOTE-042研究：帕博利珠单抗用于PD-L1 TPS≥1% NSCLC患者的5年随访数据更新

4. KEYNOTE-189和KEYNOTE-407研究及帕博利珠单抗真实世界数据：
Garassino MC，et al. J Clin Oncol;.2023; 41(11): 1992–1998.
Novello S,et al.J Clin Oncol. 2023; 41(11): 1999–2006.
Ricciuti B, et al.WCLC 2023.OA14.04.
Gadgeel SM,et al.WCLC 2023.OA14.05.

5. A Phase 3 Study of Serplulimab Plus Chemotherapy as First-Line Treatment for Squamous Non-small-Cell Lung Cancer (ASTRUM-004)(Zhou C,et al.WCLC 2023.OA09.05.)
ASTRUM-004研究：斯鲁利单抗联合化疗一线治疗鳞状NSCLC的3期研究

6. IMpower151: Phase III Study of Atezolizumab + Bevacizumab + Chemotherapy in 1L Metastatic Nonsquamous NSCLC (Zhou C,et al.WCLC 2023.OA09.06.)
IMpower151：ABCP方案一线治疗转移性非鳞NSCLC的Ⅲ期研究结果

7. CameL研究（卡瑞利珠单抗联合化疗一线治疗驱动基因阴性晚期非鳞NSCLC）、CameL-sq研究（卡瑞利珠单抗联合化疗一线治疗鳞状NSCLC）四年结果：Zhou C, et al. JTO. 2023

8. RATIONALE-304 研究: Shun Lu, et al.AACR 2023. LB289.
RATIONALE-304 研究：替雷利珠单抗联合化疗一线治疗驱动基因阴性NSCLC的III期临床研究

替雷利珠单抗另外研究结果：
1)Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients
替雷利珠单抗联合化疗一线治疗晚期老年（年龄≥70岁）非小细胞肺癌患者的研究

2)Metastatic Non-small Cell Lung Cancer – Immunotherapy – TIPs.报告题目：Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer(WCLC EP11.04. )
替雷利珠单抗联合化疗前使用曲拉西利一线治疗晚期鳞状NSCLC

9. Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.( Zhou C, et al.  Nat Cancer. 2023 Jun;4(6):860-871.)
GEMSTONE-302 研究：舒格利单抗联合化疗作为转移性NSCLC的一线治疗

10. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes. Eur J Cancer. 2023 Apr:183:174-187.
CheckMate 9LA研究2年患者报告结局：转移性非小细胞肺癌一线治疗中纳武利尤单抗联合伊匹木单抗加两个周期化疗与四个周期单纯化疗的比较

11. DUBHE-L-303: A phase III, multicenter, double-blinded, randomized, active-controlled study on the efficacy and safety of QL1706 with chemotherapy (CT) as First-line (1L) therapy for PD-L1 negative advanced or metastatic non-small-cell lung cancer (NSCLC)，（2023 ASCO ）
III期、多中心、双盲、随机、主动对照研究DUBHE-L-303：评估QL1706联合化疗作为PD-L1阴性晚期或转移性NSCLC一线疗法的有效性和安全性

12. The application of immunotherapy combined with anti-angiogenic agents and chemotherapy in advanced non-small cell lung cancer with driver gene-negative status. （Hou Q, Liu F, Chen C. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(07): 775-779.）
免疫疗法联合抗血管生成药物和化疗在驱动基因阴性的晚期非小细胞肺癌的研究

13. Overall survival from a phase II randomised double-blind trial（PERLA)）of dostarlimab（dostar）+ chemotherapy（CT） vs pembrolizumab（pembro）+ CT in metastatic non-squamous NSCLC（2023 ESMO LBA64）
II期随机双盲PERLA研究：对比dostarlimab联合化疗 vs 帕博利珠单抗联合化疗治疗转移性非鳞状NSCLC的总生存率

后线
1. Phase 1b/2 study of surufatinib in combination with docetaxel as second-line treatment of advanced driver-gene negative non-squamous non-small cell lung cancer (NSCLC).（2023 ASCO Abstract e21087.）
索凡替尼联合多西他赛二线治疗驱动基因阴性晚期非鳞NSCLC研究

2. Tumor treating field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.（2023 ASCO abstract LBA9005.）
LUNAR 3 期随机研究：铂类治疗失败后，转移性NSCLC的肿瘤电场治疗（TTFields）与标准疗法

3. SAPPHIRE: Phase 3 study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC).（ESMO Congress 2023, LBA63）
SAPPHIRE研究：sitravatinib+纳武利尤单抗治疗晚期非鳞状NSCLC的III期研究
 
SESSION5：SCLC研究进展

1.  EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)（2023 ESMO）
EXTENTORCH研究：特瑞普利单抗对比安慰剂联合化疗一线治疗广泛期小细胞肺癌

2.  SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).  (2023 ASCO)
II期随机 SWOG S1929研究：SLFN11阳性广泛期小细胞肺癌患者接受阿替利珠单抗vs阿替利珠单抗+talazoparib维持治疗

3.  Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial. (2023 WCLC)
一项随机、双盲、III期试验：Benmelstobart+安罗替尼+化疗作为广泛期SCLC的一线治疗方案

4. Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results. (2023WCLC)
一项伞式扩展研究结果：IMpower133研究中接受阿替利珠单抗治疗的广泛期SCLC患者5年生存率

5. Phase I Dose Escalation Trial Of The DLL3/CD3 Igg-Like T Cell Engager BI 764532 In Patients with DLL3+ Tumors: Focus on SCLC. (2023 WCLC)
一项I期聚焦于SCLC的剂量递增试验：IgG样T细胞重定向DLL3/CD3双抗BI 764532用于DLL3阳性患者

6. First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study. (2023 WCLC)
III期RATIONALE-312研究：一线化疗±替雷利珠单抗用于广泛期SCLC

7. Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study. (2023 WCLC)
一项1/2期亚组研究分析：Ifinatamab Deruxtecan (DS-7300) 用于难治性SCLC

8. Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase 2 DeLLphi-301 study. (2023 ESMO)
II期DeLLphi-301研究的初步分析：Tarlatamab用于既往接受过治疗的SCLC患者

9.  Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase 2 TROPiCS-03 basket trial. (2023 ESMO)
II期TROPiCS-03篮子试验：戈沙妥珠单抗（SG）用于ES-SCLC的二线治疗

10.  Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): the Phase 1/2 LUPEP study. (2023 ESMO)
I/II期LUPER研究：芦比替定 (LUR)联合帕博利珠单抗(PBL)治疗复发性小细胞肺癌

11.  Antitumor Activity and Safety Profile of Trilaciclib in Chinese patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) receiving Chemotherapy (TRACES): Updated results from TRACES. (2023 ESMO)
TRACES研究更新结果：曲拉西利在接受化疗的广泛期小细胞肺癌中国患者中的抗肿瘤活性和安全性

SESSION6：肺癌领域ADC等新型治疗研究进展
1.  Final data from a phase II study（TACTI-002）of eftilagimod alpha （soluble LAG-3）& pembrolizumab in 2nd line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors. （2023 ELCC）
II期TACTI-002研究最终分析：eftilagimod alpha（可溶性LAG3）+帕博利珠单抗二线治疗转移性 NSCLC 患者的疗效

2.  Safety and efficacy of tusamitamab ravtansine in combination with pembrolizumab ± chemotherapy in patients with CEACAM5-positive nonsquamous NSCLC（CARMEN-LC05 phase 2 study）.（2023 ELCC）
II期CARMEN-LC05研究：Tusamitamab ravtansine+帕博利珠单抗±化疗用于CEACAM5 阳性非鳞状NSCLC患者的安全性和有效性

3. Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung  Cancer: Preliminary Results of the EVOKE-02 Study
EVOKE-02研究的初步结果：戈沙妥珠单抗（Sacituzumab Govitecan，SG）联合帕博利珠单抗一线治疗转移性非小细胞肺癌

4. HERTHENA-Lung02: A randomized Phase 3 study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR tyrosine kinase inhibitor.（2023 AACR）
HERTHENA-Lung02：patritumab deruxtecan对比铂类化疗用于第三代 EGFR TKI进展后局部晚期或转移性EGFR突变NSCLC患者的随机III期研究

5.  Pembrolizumab with and without sacituzumab govitecan as first-line treatment for metastatic non-small-cell lung cancer （NSCLC） with PD-L1 TPS ≥50%: phase 3 KEYNOTE-D46/EVOKE-03 study.（2023 AACR）
帕博利珠单抗±sacituzumab govitecan用于PD-L1 TPS ≥ 50%转移性NSCLC患者的一线治疗：III 期 KEYNOTE-D46/EVOKE-03 研究

6. Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase 3 study TROPION-Lung01.（2023 ESMO）
III期随机化TROPION-Lung01研究结果：Datopotamab deruxtecan（Dato-DXd）对比多西他赛治疗既往接受过治疗的晚期/转移性NSCLC 

7.  TROPION-Lung02: Datopotamab deruxtecan （Dato-DXd） plus pembrolizumab （pembro） with or without platinum chemotherapy （Pt-CT） in advanced non-small cell lung cancer（aNSCLC）.（2023 ASCO）
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) 联合帕博利珠单抗±含铂化疗治疗晚期NSCLC

8. Datopotamab Deruxtecan (Dato-DXd) + Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04（2023 WCLC）
TROPION-Lung04中期分析结果：Datopotamab Deruxtecan (Dato-DXd) 联合度伐利尤单抗±卡铂治疗晚期/转移性NSCLC

9. TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs). (2023 ESMO)
TROPION-Lung05: Datopotamab deruxtecan （Dato-DXd）治疗具有可靶向基因组改变（AGAs）的非小细胞肺癌（NSCLC）

10. Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.（2023 ASCO）
LUNAR III期研究：电场疗法联合标准治疗用于含铂化疗失败的晚期NSCLC患者

11. Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.（2023 ASCO）
一种新型PD-1/VEGF双特异性抗体AK112联合化疗用于无AGA晚期NSCLC患者的疗效和安全性

12. SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study.
SI-B001+化疗治疗局部晚期或转移性 EGFR/ALK 野生型非小细胞肺癌患者的结果：一项 II 期、多中心、开放标签研究

13 BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. （2023 ASCO）
靶向EGFR/HER3双特异性抗体ADC药物BL-B01D1用于局部晚期或转移性实体瘤：I期研究结果

14. Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFR TKI and Platinum-Based Chemotherapy: HERTHENA-Lung01.（2023 WCLC）
HERTHENA-Lung01研究：Patritumab Deruxtecan（HER3-DXd）用于EGFR-TKI和含铂化疗治疗后的EGFR突变NSCLC

15.  TTFields and Immune-Checkpoint Inhibitor in Metastatic Non-Small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study.（2023 WCLC）
III期LUNAR研究PD-L1亚组：TTFields联合免疫检查点抑制剂治疗转移性NSCLC

16. Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: overall survival data from the 1st line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (Phase II). (2023 ESMO)
抗原呈递细胞激活剂eftilagimod α（可溶性LAG-3）联合帕博利珠单抗一线治疗非小细胞肺癌（NSCLC）队列的总生存数据（II期）

17. BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Non-Small Cell Lung Cancer: Updated results from first-in-human phase 1 study. (2023 ESMO)
BL-B01D1，首创EGFRxHER3双特异性抗体ADC用于非小细胞肺癌患者：首次人体I期研究的最新结果

18.     First-in-Human Study of ABBV-637, an EGFR-targeting BCL-XL–Inhibiting Antibody-Drug Conjugate Combined With Osimertinib (OSI) in Relapsed/Refractory, EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) . (2023 ESMO)
靶向EGFR的BCL-XL抑制抗体药物偶联物ABBV-637联合奥希替尼（OSI）治疗复发/难治性EGFR突变的非小细胞肺癌（NSCLC）的首次人体研究

19. Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: results from HERTHENA-Lung01. (2023 ESMO)
HERTHENA-Lung01研究：HER3-DXd在既往经治晚期EGFR突变NSCLC患者的颅内疗效

20. Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC) . (2023 ESMO)
靶向PTK7 ADC cofetuzumab pelidotin用于PTK7阳性复发性NSCLC患者的Ib期研究

21. Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
首创、RAS选择性、Ras-Multi（ON）抑制剂三重复合物RMC-6236用于KRAS突变PDAC和NSCLC患者的初步临床活性。 

22.  Safety and efficacy of tusamitamab ravtansine in combination with pembrolizumab ± chemotherapy in patients with CEACAM5-positive nonsquamous NSCLC (CARMEN-LC05 phase II study).（2023 ELCC 13MO）
CARMEN-LC05研究：tusamitamab ravtansine联合帕博利珠单抗±化疗在CEACAM5阳性非鳞状NSCLC患者中的安全性和疗效

Session1：宫颈癌研究进展
早期宫颈癌治疗
NCT01658930: 低危早期宫颈癌患者行单纯子宫切除术后3年盆腔复发率非劣于根治性子宫切除术(2.52%VS2.17%)。(2023ASCO LBA5511)
 
局晚期宫颈癌治疗
GCIG INTERLACE研究：诱导化疗后放化疗（CRT）可显著改善局晚期宫颈癌（LACC）患者PFS 和 OS，5 年 PFS 率为 73%，5 年 OS 率为 80%，或可作为治疗新标准。（2023 ESMO LBA8）

KEYNOTE-A18研究：在高危局部晚期宫颈癌患者中，与安慰剂+ 同步放化疗（CCRT） 相比，帕博利珠单抗+ CCRT 可显著改善患者PFS，OS 有延长趋势，安全性可控。（2023ESMO LBA 38）

COLIBRI研究（COLIBRI试验）：标准放化疗之前使用纳武利尤单抗联合伊匹木单抗新辅助治疗FIGO IB3-IVA期宫颈鳞状细胞癌患者是安全的，并协调了新的免疫反应。RTCT后6个月，原发性肿瘤的CR率为82.5%。（2023 ASCO 5501）

GOTIC-018研究：在接受同步放化疗的局晚期宫颈癌（LACvCa）患者中，预先/联合使用纳武利尤单抗+同步放化疗，随后纳武利尤单抗维持治疗安全有效，同步放化疗前给予纳武利尤单抗、同步放化疗联合纳武利尤单抗组ORR分别为100%、93%，完全缓解率均为73.3%，12个PFS率为100%。（2023 ASCO 5519）

NACI研究:卡瑞利珠单抗+化疗新辅助治疗局部晚期宫颈癌ORR100% (95%CI, 95.38 ~ 100)，完全缓解(CR)率为17.95%，部分缓解率82.05%，pCR率39.47% (95%CI, 28.44 ~ 51.35)。（2023 ASCO 5520）

NRG GY006研究：顺铂放化疗（CRT）基础上添加Triapine不能改善局部晚期宫颈癌和阴道癌患者OS。（2023ASCO 55020）

NCT04368273：特瑞普利单抗联合顺铂为基础的同步放化疗治疗局部晚期宫颈癌耐受性良好，展现出良好的抗肿瘤活性，治疗3个月后ORR为100%，可能是该患者群体的一种新的治疗选择。（2023ESMO 767P）

NCT04678791：相比同步放化疗，尼妥珠单抗联合同步放化疗治疗局部晚期宫颈鳞癌显示出更长的生存趋势，尼妥珠单抗联合同步放化疗和同步放化疗组中位PFS分别为9.5 和7.0个月（P=0.129）；ORR显著改善，两组ORR分别为86.39%和76.39%（P=0.028），且耐受性良好。（2023ESMO 759P）
 
复发转移宫颈癌治疗
一线治疗
BEATcc研究：阿替利珠单抗联合化疗＋贝伐珠单抗一线治疗复发/转移（R/M）宫颈癌可显著改善患者生存，中位OS延长至2.5年。（2023ESMO LBA39）

KEYNOTE-826 研究：化疗±贝伐珠单抗基础上添加帕博利珠单抗可显著降低患者死亡风险，PD-L1 CPS≥1人群死亡风险降低40%，全人员死亡风险降低37%，CPS≥10人群死亡风险降低42%，且安全性可控。（2023ASCO 5500）

单臂II期研究：QL1706联合化疗+贝伐珠单抗一线治疗复发或转移性宫颈癌耐受性良好，抗肿瘤活性良好，ORR为81% (95% CI, 68.6-90.1) ，DCR为98.3% (95% CI, 90.8-100.0)。mPFS为14.3个月(95% CI, 9.2-NE)。（2023ESMO 743MO）

特瑞普利单抗联合贝伐珠单抗和含铂化疗治疗难治性、复发/转移性宫颈癌患者ORR为77.3%、DCR为95.5%，安全性良好。（2023 SGO oral 211）

II期研究（NCT05247619）：替雷利珠单抗联合贝伐珠单抗及含铂化疗一线治疗复发宫颈癌客观缓解率（ORR）为78.4%，疾病控制率为100%。中位缓解时间（TTR）为1.5个月 （范围为1.5-4.0）。亚组分析显示：宫颈鳞癌和宫颈腺癌的ORR分别为79.4%和66.7%；PD-L1阴性、低表达和高表达患者的ORR分别为100%、71.4%和86.7%。（2023ASCO 5531）
 
二线治疗
 
innovaTV 301研究：与化疗相比，Tisotumab vedotin (TV)单药后线治疗复发/转移性宫颈癌在 OS、PFS 和 ORR 方面显示出具有临床意义的统计学显著改善，在 2L/3L r/mCC 患者中具有可控且可耐受的安全性。（2023 ESMO LBA9）

II期研究：相比研究者选择的化疗，卡瑞利珠单抗联合法米替尼用于复发/转移性宫颈癌ORR、中位PFS、中位OS表现更优，且安全性可控。（2023ESMO LBA44）

AdvanTIG-202研究：无论 PD-L1 表达如何，替雷利珠单抗联合ociperlimab用于复发/转移性宫颈癌(CC)都显示出有希望的抗肿瘤活性和持久反应，并且在既往接受过治疗的 R/M CC 患者中具有良好的耐受性。（2023ESMO 744MO）

1b/3期研究：SHR-1701联合铂类化疗及BP102（贝伐珠单抗生物类似物）治疗持续、复发或转移性宫颈癌ORR为77.4%，DCR达93.5%，6个月无进展生存率达93.5%。安全性可控。（2023 ASCO 5529）

重组人5型腺病毒(H101)瘤内注射治疗接受过至少一线系统治疗或无法耐受化疗的P/R/M CC患者，3个月LC率为73.5%，ORR 69.4%，DCR 81.6%，6个月和12个月 PFS 率分别为75.77%和59.66%，OS 率分别为92.94%和73.83%，中位PFS和OS未达到。（2023ESMO 757P）
 
Session2：卵巢癌研究进展
新诊断卵巢癌治疗
辅助治疗
OVHIPEC-1研究10年随访数据：新辅助化疗后接受满意中间型细胞减灭术的III期卵巢癌患者术后接受腹腔热灌注化疗（HIPEC），无复发生存率（HR 0.6, 95%CI 0.48-0.83; stratified P=0.0008）和总生存率（HR 0.7, 95%CI 0.53-0.92; stratified P=0.0113）均优于对照组患者。随时间延长，HIPEC降低复发和死亡风险的能力持续存在且愈加稳健。（2023 ASCO 5509）
 
一线维持治疗
FLAMES研究：Senaparib一线维持治疗新诊断晚期卵巢癌可使疾病进展或死亡风险降低57%， 1 年 PSF 率为 72.2%，无论晚期卵巢癌患者是否存在 BRCA 突变，均可观察到 PFS 的获益趋势。（2023ESMO LBA36）

DUO-O研究：相比对照组，PC+贝伐珠单抗+度伐利尤单抗一线治疗后贝伐珠单抗+度伐利尤单抗+奥拉帕利维持治疗可显著延长新诊断非BRCAm晚期OC患者PFS，且各亚组分析获益一致。安全性总体上与每种药物的已知安全性一致。（2023ASCO LBA5506）

ALTER-GO-010研究：安罗替尼联合卡铂/紫杉醇一线治疗序贯安罗替尼单药维持治疗新诊断晚期卵巢癌展现出良好疗效，6 个月和 9 个月的 PFS 率均为 100%。（2023 ASCO 5575）

PRIMA研究：尼拉帕利一线维持治疗新诊断原发性晚期卵巢癌患者HRD亚组PFS显著延长。（2023ESMO GC 33O）

PAOLA-1研究：奥拉帕利联合贝伐珠单抗维持治疗显著提高新诊断的晚期卵巢癌HRD阳性患者OS和PFS。（2023 ESMO GC 32O）

SOLO1研究7年随访数据：奥拉帕利维持治疗新诊断晚期BRCA突变卵巢癌患者显著改善OS，7年OS率67%。（J Clin Oncol. 2023 Jan 20;41(3):609-617.）

CHAR1ZMA研究：真实世界中，尼拉帕利一线维持治疗的患者，在治疗前90天内对药物毒性进行有效的临床管理可帮助患者继续治疗并获得最大化的治疗获益。（2023 ESMO 789P）
 
复发性卵巢癌治疗
铂敏感复发卵巢癌
OPEB-01研究：非BRCA 1/2突变的PSR上皮性卵巢癌患者在二线铂类化疗完全或部分缓解后，应用三联疗法（奥拉帕利+贝伐珠单抗+帕博利珠单抗）一直维持到疾病进展或不可接受的毒性，6个月的PFS率为88.6% (95%CI，75.4～96.2)，中位PFS尚未达到。在安全性可控。（2023 ASCO 5584）

C-PATROL研究：在真实世界中，BRCAm PSR患者使用奥拉帕利维持治疗可获得较好的生存获益，且安全性良好。（2023ESMO 802P）

NRG-GY004研究：奥拉帕利 (O) 或西地尼布联合奥拉帕利 (C+O) 与标准治疗 (SOC) 铂类化疗相比虽然可延长gBRCAm 患者中位 PFS，但并不能改善铂敏感复发卵巢癌患者无进展生存期 (PFS), O 和 C+O 的 (总生存期)OS 风险比均超过 1。（2023ESM0 LBA45）

CHIPOR研究：EOC患者首次铂敏感复发后接受二线含铂化疗联合二次完全肿瘤细胞减灭术时进行HIPEC可显著改善OS和腹膜PFS。（2023 ASCO 5510）

ANITA研究：阿替利珠单抗联合含铂化疗+尼拉帕利维持治疗并不能改善无铂间期>6个月复发卵巢癌患者 PFS 或 ORR。（2023 ESMO LBA37）
 
铂耐药复发卵巢癌
MIRASOL研究：与IC化疗相比，MIRV治疗叶酸受体α（FRα）高表达铂耐药卵巢癌可显著延长患者PFS和OS，安全性可控，或可作为FRα阳性铂耐药卵巢癌治疗新标准。（2023 ASCO LBA5507）

OVAL 研究：紫杉醇周疗± ofranergene obadenovec (VB-111)治疗铂耐药卵巢癌的III期随机对照研究。（2023 ASCO 5505）

吉西他滨联合或不联合ATR抑制剂berzosertib治疗铂耐药卵巢癌的随机II期研究：吉西他滨/berzosertib与吉西他滨单药相比未显著改善铂耐药高级别浆液性卵巢癌患者OS。在铂耐药的情况下，PFI≤3个月的患者和肿瘤复制应激(RS)低的患者可能通过吉西他滨加用berzosertib获得生存优势。（2023 ASCO 5512）

NRG-GY023研究：与标准化疗（SOC）相比，度伐利尤单抗联合奥拉帕利和cediranib（DOC）与奥拉帕利联合cediranib（OC）或度伐利尤单抗联合cediranib（DC）并不能改善既往接受贝伐珠单抗治疗患者PFS。（2023 ESMO 746MO）

WEE1抑制剂azenosertib (ZN-c3)联合化疗(CT)治疗铂类耐药或难治性(R/R )上皮性卵巢癌、腹膜癌或输卵管癌( EOC ) 耐受性良好，部分缓解(PR)率为26.6%，中位无进展生存期(PFS)为9.03个月。Cyclin E1高表达肿瘤患者(CT获益欠佳的亚组)与低表达肿瘤患者相比，ORR和PFS改善更优。（2023 ASCO 5513）
 
经治卵巢癌
STRO-002-GM1研究：在FolRα TPS＞25%的复发性OC中，Luveltamab tazevibulin（luvelta）起始剂量4.3-5.2 mg/kg展现出良好的抗肿瘤活性。（2023 ASCO 5508）

NCT04707248：R-DXd单药用于经治卵巢癌（OVC）患者展现出良好潜力，经确认的总缓解率 (RECIST v1.1) 为 38%，4.8 mg/kg 剂量患者ORR 为67%，6.4 mg/kg剂量患者ORR 为 33%，8.0 mg/kg 剂量患者ORR为31%。（2023ESMO 745MO）

BOUQUET研究：对于既往多线治疗的低级别浆液性卵巢癌（LGSOC）/中肾样腺癌（MLA）患者，cobimetinib是一种有潜力的治疗方案，cORR达33%，疾病控制率（DCR）为89%，耐受性与既往报道数据一致。（2023ESMO 747MO）
 
Session2：子宫内膜癌研究进展
局晚期治疗
帕博利珠单抗用于错配修复缺陷型EC患者新辅助治疗影像学ORR为37.5%。50%的患者获得病理学缓解，其中20%为显著病理学缓解。（2023ESMO 742MO）

NRG Oncology GOG258研究：相比单独化疗，化疗+放疗降低了局部复发率，但并不能改善局晚期子宫内膜癌患者OS和PFS，且远处转移率升高。（2023 SGO LBA 213）
 
一线治疗
AtTEnd研究：在标准CP化疗中加入阿替利珠单抗，可显著改善晚期/复发性子宫内膜癌患者PFS，尤其是dMMR患者。（2023 ESMO LBA40）

DUO-E/GOG-3041/ENGOT-EN10研究：标准一线CP化疗中增加度伐利尤单抗，随后度伐利尤单抗±奥拉帕利维持治疗可显著改善患者PFS，尤其是pMMR患者，这是首个证明度伐利尤单抗+奥拉帕利具有PFS获益，能为晚期或复发子宫内膜癌患者提供新治疗选择的Ⅲ期研究。（2023ESMO LBA41）

NRG GY018研究：与卡铂/紫杉醇加安慰剂相比，帕博利珠单抗加卡铂/紫杉醇治疗在子宫内膜癌患者中显著改善PFS，随着随访时间的延长，dMMR和pMMR患者接受帕博利珠单抗治疗的获益程度仍然保持，并且ORR和DOR有显著提高。（2023 ESMO LBA43）

RUBY研究：与单纯CP化疗相比，Dostarlimab+CP在总人群和dMMR/MSI-H人群中均观察到有临床意义的BICR评估的PFS改善，BICR评估的PFS和既往INV评估的PFS风险比（HR）一致。其他BICR评估的次要研究终点中，也看到了Dostarlimab+CP与既往INV评估结果一的临床获益。（2023 ASCO 5503）

RUBY研究患者报告结局：Dostarlimab联合卡铂/紫杉醇治疗原发性晚期或复发性子宫内膜癌在显著改善患者PFS的同时可维持患者HRQoL，该研究结果进一步为D+CP作为pA/rEC标准治疗提供了循证支持。（2023 ASCO 5504）

RUBY试验：按分子分型分析Dostarlimab+化疗治疗原发性晚期或复发子宫内膜癌的PFS和OS结局，结果显示在dMMR/MSI-H、NSMP和TP53亚组中，Dostarlimab+CP与PFS和OS改善相关，并且对于原发性晚期或复发子宫内膜癌治疗具有重要的预后价值，POLε突变患者的预后最好。（2023ESMO 740MO）

UTOLA 研究：含铂化疗(CT) 一线治疗后疾病控制的晚期/转移性EC 患者，奥拉帕利维持治疗可显著延长 HRD+晚期/转移性（M+)子宫内膜癌中位PFS，为5.4 个月 (90% CI 3.6-9.6)，且不受 P53状态影响。CT 获得 CR 的患者，奥拉帕利维持治疗PFS 达到 8.8 个月。（2023 ESMO LBA42）
 
二线/后线治疗
免疫治疗
阿替利珠单抗联合卡铂和紫杉醇治疗晚期/复发性子宫内膜癌的III期双盲随机安慰剂对照试验。（2023 ESMO LBA40）

CAP 04研究（单臂II期研究）：卡瑞利珠单抗联合阿帕替尼治疗既往接受一次系统治疗失败的晚期或复发性子宫内膜癌，展现出令人鼓舞的抗肿瘤活性，ORR为44.4%，中位PFS为6.4个月，中位OS达21个月。（2023 ASCO 5516）

GEICO 70-E：阿维鲁单抗+聚乙二醇化脂质体阿霉素治疗复发/转移性EC患者ORR为19.5%，中位缓解持续时间为6.6个月。（2023 ASCO 761P）

安罗替尼联合信迪利单抗治疗晚期或复发性子宫内膜癌中位OS为17.8个月 （95%CI，9.4-26.3）。与MSS/pMMR患者相比，MSI-H/dMMR患者的OS获益更显著（NA vs. 13.3个月；HR=0.15，95%CI，0.33-0.70，P = 0.006）。（2023 ASCO 5598）

NRG GY018研究：帕博利珠单抗联合 CP 治疗晚期或复发性 dMMR 和 pMMR子宫内膜癌患者未见 PFS差异。随着更长的临床随访，采用帕博利珠单抗治疗的两个患者队列的获益程度持续维持，ORR 和 DOR 显著改善。（2023 ESMO LBA43）
 
ADC治疗
STRO-002-GM1研究：Luveltamab tazevibulin治疗复发/进展性上皮性子宫内膜癌展现出良好疗效和可控的安全性。（2023 ESMO 741MO）

DP-02研究：T-DXd治疗局部晚期、不可切除、经治转移性HER2表达阳性子宫内膜癌ORR为57.5%，展现出持续缓解的能力，而在IHC 3+表达亚组中，临床疗效更为突出，ORR达到84.6%，同时亦显示出更长的持续缓解能力。（2023 ASCO LBA3000）

Session1：可切除/潜在可切除肝癌治疗进展
新辅助
Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trial HAIC 新辅助治疗改善可切除的超米兰标准肝癌患者的长期预后 (2023 ASCO, 4023)

Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable HCC. Notable-HCC中期报告：新辅助PD-1和立体定向放射治疗可切除HCC患者的Ib期研究(2023 ESMO, 957P)

A Prospective, Phase II Clinical Study of Tislelizumab monotherapy or in Combination with Lenvatinib for neoadjuvant Treatment of Resectable Hepatocellular Carcinoma替雷利珠单抗单药或联合仑伐替尼用于可切除肝癌新辅助治疗的前瞻性II期临床研究(2023 ESMO, 1015TiP)
 
围术期
A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage双艾组合用于可切除肝癌围手术期治疗的病理缓解情况 (2023 ASCO, 4126)

A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage卡瑞利珠单坑联合阿帕替尼治疗中高复发风险可切除肝细胞癌围手术期的II/III期研究：II期主要病理反应的初步结果 (2023 ASCO, 4126)

Camrelizumab in combination with apatinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: A prospective, single-arm, phase 2 study. 卡瑞利珠单抗联合阿帕替尼作为高复发风险的肝细胞癌患者的围手术期治疗：一项前瞻性单臂II期研究(2023 ASCO, 4120)
 
术后辅助
HAIC combined with anlotinib and TQB2450 as adjuvant therapy for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after hepatectomy: A single-centre, non-randomised, open clinical study HAIC 联合安罗替尼和 TQB2450 用于肝癌术后辅助治疗的单臂探索性研究(2023 ESMO, 951P)

Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation IMbrave050：T+A 用于术后辅助治疗不太影响患者生活质量(2023 ASCO, 4002)

Phase 2 study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion替雷利珠单抗联合干扰素-α辅助治疗和主动监测在微血管浸润的肝细胞癌患者中的2期研究(2023 ESMO, 956P)

Efficacy and safety of recombinant human adenovirus type 5 injection combined with transhepatic arterial embolization sequential thermal ablation for medium-and high-risk recurrent liver cancer: a prospective, open-label, randomized controlled study重组人5型腺病毒注射液联合经肝动脉栓塞序贯热消融治疗中高危复发性肝癌的疗效和安全性：一项前瞻性、开放标签、随机对照研究(2023 ESMO, 1014TiP)

A prospective, open-label, randomized, controlled trial of radiofrequency ablation versus stereotactic body radiation therapy for recurrent small hepatocellular carcinoma. 射频消融术与立体定向身体放射治疗复发性小肝癌的前瞻性、开放标签、随机对照试验(2023 ASCO, 4096)

Adjuvant immune checkpoint inhibitors and association with recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): A prospective cohort study. 免疫检查点抑制剂作为辅助治疗与肝癌术后无复发生存的关系：一项前瞻性队列研究(2023 ASCO, 4119)

Adjuvant transarterial chemoembolization with sorafenib for patients with hepatocellular carcinoma with portal vein tumor thrombus after surgery: A phase Ⅲ, multicenter, randomized, controlled trial索拉非尼联合经动脉化疗栓塞辅助治疗合并门脉癌栓肝细胞癌：一项III期、多中心、随机对照试验(2023 ASCO GI, Rapid Abstract 493)
 
转化治疗
Donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II trial (DoHAICs study) 肝动脉灌注化疗（HAIC）联合多纳非尼和信迪利单抗用于不可切除肝癌转化治疗的 II 期研究（DoHAICs）(2023 ESMO, 999P)

Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study仑伐替尼联合信迪利单抗用于不可切除肝癌的转化治疗的 II 期研究 (2023 ESMO, 946P)

Efficacy and Safety of Curative Hepatectomy after Conversion Therapies for Initial Unresectable Hepatocellular Carcinoma: A Multicenter Propensity Score Matching Study一项多中心倾向评分匹配研究：原发性不可切除肝细胞癌转化治疗后肝切除术的疗效和安全性(2023 ESMO, 998P)

Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma替雷利珠单抗联合TKIs和FOLFOX4-HAIC转化治疗不可切除肝癌的疗效和安全性(2023 ESMO,1002P)
 
手术/局部治疗进展
Transarterial Chemoembolization with Idarubicin versus Epirubicin for Hepatocellular Carcinoma: an Interim Analysis of a Multicentre, Randomized Controlled phase 3 trial伊达比星对比表柔比星经动脉化疗栓塞治疗肝细胞癌：一项多中心随机对照3期试验的中期分析(2023 ESMO, 982P)

Efficacy and safety of HepaSphere drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. 载药微球-TACE联合HAIC治疗晚期肝细胞癌的疗效和安全性(2023 ASCO, 4122)
 
Session2：晚期肝癌治疗进展
一线治疗
AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC) Ociperlimab（TIGIT 抗体）用于晚期肝癌一线治疗的 II 期研究（AdvanTIG-206） (2023 ESMO, 945MO)

IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma仑伐替尼联合纳武利尤单抗用于晚期肝癌一线治疗的II期研究（IMMUNIB） (2023 ESMO, 955P)

The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial仑伐替尼联合卡度尼利单抗用于晚期肝癌一线治疗的 Ib/II 期研究 (2023 ESMO, 947P)

Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries T+A 方案进展后治疗的亚太地区的真实世界研究 (2023 ESMO, 970P)

Phase (Ph) I/II study of sitravatinib (Sitra) alone or with tislelizumab (TIS) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/ GEJC) Sitravatinib 联合替雷利珠单抗用于晚期肝癌的 Ib/II 期研究（SAFFRON-104）(2023 ESMO, 948P)

Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC) MORPHEUS-Liver：TIGIT 抗体用于晚期肝癌一线治疗的 Ib/II 期研究(2023 ASCO, 4010)

Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study. REPLACEMENT：T+A 组合用于不适合 TACE 的中期肝癌的 II 期研究(2023 ASCO, 4125)

An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma. QL1706 或 QL1604 联合贝伐珠单抗用于晚期肝癌一线治疗的 Ib/II 期研究(2023 ASCO, 4077)

Phase II clinical study of sorafenib combined with tislelizumab in the treatment of first-line unresectable hepatocellular carcinoma and the predictive effect and correlation of CTC索拉非尼联合替雷利珠单抗一线治疗不可切除肝癌的II期临床研究及CTC的预测作用及相关性(2023 ESMO, 950P) 

Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): a multicenter, single-armed, real-world study仑伐替尼联合经动脉化疗栓塞（TACE）初始治疗晚期肝细胞癌的前瞻性、观察性试验（PROLONG）的有效性和安全性：一项多中心、单臂、真实世界的研究(2023 ESMO, 952P)

Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: a single arm, phase Ⅱ clinical trial放疗联合替雷利珠单抗+安罗替尼一线治疗肝细胞癌：单臂Ⅱ期临床试验(2023 ESMO, 954P)

Safety and Efficacy of Durvalumab plus Hepatic Artery Infusion Chemotherapy in HCC with Severe Portal Vein Tumor Thrombosis (Vp3/4) – the DurHope Study 度伐利尤单抗联合肝动脉灌注化疗治疗伴重度门静脉癌栓（Vp3/4）的肝细胞癌的安全性和有效性——DurHope研究(2023 ESMO, 983P)

Analyzing effectiveness and safety of standard-dose and low-dose bevacizumab combination with atezolizumab in patients with unresectable hepatocellular carcinoma: a multi-institutional study in Taiwan标准剂量和低剂量贝伐珠单抗联合阿替利珠单抗治疗不可切除肝癌的有效性和安全性分析：台湾多机构研究(2023 ESMO, 992P)

Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study在一项多中心回顾性研究中，经动脉化疗栓塞联合多纳非尼加/不加PD-1抑制剂治疗最初不可切除肝细胞癌(2023 ESMO, 996P)

Atezolizumab plus bevacizumab combined with transarterial chemoembolization and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with high tumor burden阿替利珠单抗和贝伐珠单抗联合经动脉化疗栓塞和肝动脉灌注化疗治疗不可切除的高肿瘤负荷肝细胞癌(2023 ESMO, 1005P)

The safety and efficacy of PD-1 inhibitor (Sintilimab) combined with conventional transarterial chemoembolization (cTACE) for the initial treatment of the stage BCLC B hepatocellular carcinoma (HCC) beyond up-to-seven criteriaPD-1抑制剂（信迪利单抗）联合常规经动脉化疗栓塞（cTACE）初始治疗BCLC - B期up-to-seven标准的肝细胞癌（HCC）的安全性和有效性(2023 ESMO, 1008P)

A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus TACE联合仑伐替尼+信迪利单抗治疗肝癌合并门静脉癌栓的前瞻性研究(2023 ESMO, 1011P)

Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 European/North American (EU/NA) subgroup. 替雷利珠单抗与索拉非尼在不可切除肝细胞癌（HCC）一线（1L）治疗中的作用：RATIONALE-301欧洲/北美（EU/NA）亚组(2023 ASCO, 4082)

Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC). 双免组合STRIDE方案（T+D）在不可切除肝癌患者中免疫相关不良事件的预后——HIMALAYA III期临床研究(2023 ASCO, 4004)

Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS). 危险因素对替雷利珠单抗一线治疗不可切除肝细胞癌患者总生存率（OS）的影响(2023 ASCO, 4083)

Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial. 替雷利珠单抗联合仑伐替尼加TACE治疗不可切除肝细胞癌：一项单臂II期临床试验(2023 ASCO, 4111)

Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma. TACE联合酪氨酸激酶抑制剂和卡瑞利珠单抗治疗晚期不可切除肝细胞癌的安全性和有效性 (2023 ASCO, 4079)

NRG/RTOG 1112:索拉非尼单药对比立体定向放射治疗(SBRT) 序贯索拉非尼用于肝细胞癌患者的一项随机Ⅲ期临床研究(2023 ASCO GI, Oral 489)

替雷利珠单抗对比索拉非尼一线治疗不可切除肝细胞癌: RATIONALE-301研究健康相关生活质量分析(2023 ASCO GI, Poster 495)

Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup替雷利珠单抗比较索拉非尼作为uHCC一线治疗：≥65岁患者亚组分析（RATIONALE-301研究）(2023 WCGIC, SO-14)

LEAP-002Ⅲ期研究;仑伐替尼联合帕博利珠单抗对比仑伐替尼联合安慰剂一线治疗对晚期肝细胞癌患者健康相关生活质量的影响(2023 ASCO GI, Poster 506)
IMbrave150:在一项阿替利珠单抗+贝伐珠单抗治疗不可切除肝细胞癌的全球3期研究的探索性分析中，探讨跳过贝伐珠单抗相比于从未跳过贝伐珠单抗对疗效的影响(2023 ASCO GI, Poster 538)

安罗替尼联合特瑞普利单抗一线治疗不可切除肝细胞癌:ALTER-H003研究结果更新(2023 ASCO GI, Poster 568)

在不可切除肝细胞癌的3期HIMALAYA研究中，曲美木单抗或度伐利尤单抗抗药物抗体的存在及其影响(2023 ASCO GI, Poster 551)

Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Tremelimumab联合度伐利尤单抗治疗不可切除肝细胞癌：四年总生存更新（HIMALAYA研究）(2023 WCGIC, SO-15)

度伐利尤单抗联合曲美木单抗用于不可切除肝细胞癌患者一线治疗的开放标签、多中心、Ⅲb期临床研究(TREMENDOUS研究) (2023 ASCO GI, TPS 628)
Comparing anti-PD-L1 with anti-PD-1 antibodies in the combination of HAIC and Lenvatinib for the treatment of unresectable hepatocellular carcinoma HAIC联合仑伐替尼和抗PD-L1抗体或抗PD-1抗体治疗不可切除肝细胞癌(2023 ASCO GI, Poster 509)
 
二线及后线治疗
Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial恩沃利单抗联合 suvemcitug 用于肝癌的后线治疗的 II 期研究 (2023 ESMO, 959P)

First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression ABSK-011 用于 FGF19-FGFR4 通路激活的肝癌二线治疗的 I 期研究 (2023 ESMO, 1012P)

A phase 1b study of E7386, a CREB-binding protein (CBP)/b-catenin interaction inhibitor, in combination with lenvatinib in patients with advanced hepatocellular carcinoma. E7386 联合仑伐替尼用于晚期肝癌治疗的 1b 期研究(2023 ASCO, 4075)

Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study瑞戈非尼联合免疫治疗对比瑞戈非尼作为晚期肝细胞癌患者的二线治疗：一项多中心真实世界研究 (2023 ESMO, 949P)

Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): a single-arm, phase 2 trial替雷利珠单抗联合瑞戈非尼作为不可切除肝细胞癌（uHCC）的二线治疗：一项单臂2期试验(2023 ESMO, 953P)

Preliminary results of radiotherapy (RT) combined with sintilimab (Sin) and bevacizumab (Bev) in advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICIs): A prospective phase II study放疗（RT）联合信迪利单抗（Sin）和贝伐珠单抗（Bev）治疗先前用免疫检查点抑制剂（ICIs）治疗的晚期肝细胞癌（HCC）的初步结果：一项前瞻性II期研究(2023 ESMO, 958P)

Hepatic arterial infusion chemotherapy (HAIC) combined with Regorafenib and PD-1 inhibitors versus Regorafenib combined with PD-1 inhibitors for second-line treatment Hepatocellular carcinoma (HCC) 肝动脉输注化疗（HAIC）联合瑞戈非尼和PD-1抑制剂对比瑞戈非尼联合PD-1抑制剂二线治疗肝细胞癌（HCC）(2023 ESMO, 977P)

Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: a retrospective, multi-center, real-world study索拉非尼或仑伐替尼治疗晚期肝细胞癌失败后序贯瑞戈非尼的疗效比较：一项回顾性、多中心、真实世界研究(2023 ESMO, 1004P)

Efficacy of nivolumab and ipilimumab in patients with hepatocellular carcinoma with prior immune-checkpoint inhibitor treatment纳武利尤单抗联合伊匹木单抗在既往接受免疫检查点抑制剂治疗的肝细胞癌患者的有效性研究(2023ASCO GI, Poster 554)

Outcomes of patients receiving lenvatinib following immunotherapy in patients with advanced hepatocellular carcinoma晚期肝细胞癌患者免疫治疗后接受仑伐替尼的研究结果(2023ASCO GI, Poster 507)

A phase II clinical trial to study the use of cabozantinib (cabo) in patients with hepatocellular carcinoma (HCC) post immunotherapy treatment卡博替尼用于免疫经治的不可切除肝细胞癌患者的II期临床研究(2023ASCO GI, Poster 571)

Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study真实世界中瑞戈非尼治疗不可切除肝细胞癌(uHCC)患者的使用剂量：前 瞻性观察性REFINE研究最终分析结果(2023ASCO GI, Poster 518)

PD-15 Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments.大型真实世界研究探索“T+A”治疗进展后应用仑伐替尼(2023 WCGIC, Abstrasct PD-15)

肠癌外科治疗
结直肠癌新辅助治疗
1.  Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)（2023ASCO-GI Oral7）
NRG-GI002研究长期结果：全程新辅助治疗（TNT）用于局部晚期直肠癌（LARC）的Ⅱ期临床研究

2. Preoperative Chemotherapy with Selective Chemoradiation versus Chemoradiation for Locally Advanced Rectal Cancer:The PROSPECT Trial (Alliance N1048)（2023ASCO LBA2）
术前化疗联合选择性化放疗对比常规化放疗治疗局部晚期直肠癌：PROSPECT研究（Alliance N1048）

3. Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial.（2023ASCO LBA3503）
对比新辅助化疗和标准治疗用于局部晚期结肠癌患者疗效的Ⅲ期随机临床研究：NeoCol研究

4. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.（2023ASCO LBA3504）
mFOLFIRINOX全程新辅助治疗对比术前放化疗用于局部晚期直肠癌患者：一项UNICANCER GI研究，PRODIGE 23 Ⅲ期研究的7年结果

5.  Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial.（2023ASCO Oral3505）
新辅助mFOLFOX6联合或不联合放疗对比氟尿嘧啶联合放疗治疗局部晚期直肠癌的长期结局：一项多中心随机Ⅲ期研究

6. Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: A randomized phase III trial (UNION)（2023ESMO LBA25）
新辅助短程放疗后卡瑞利珠单抗联合化疗对比长程化放疗后化疗治疗局部晚期直肠癌：一项随机Ⅲ期研究（UNION）

7.Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): Final results of a phase III trial（2023ESMO LBA26）
CAPOX新辅助化疗对比化放疗治疗直肠系膜筋膜未受累的局部晚期直肠癌：CONVERT Ⅲ期研究最终结果

8.Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: The NICHE-3 study（2023ESMO LBA31）
新辅助纳武利尤单抗联合relatlimab（抗LAG3）治疗局部晚期错配修复缺陷结肠癌：NICHE-3研究

9.Sustained organ preservation in patients with rectal cancer treated with total neoadjuvant therapy: Long-term results of the OPRA trial.（2023ASCO 3520PD）
接受全程新辅助治疗的直肠癌患者的持续器官保留：OPRA研究的长期结果

10.The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)（2023ESMO 595P）
DUREC研究：度伐利尤单抗联合全程新辅助治疗用于局部晚期直肠癌——一项多中心、单臂、Ⅱ期研究（GEMCAD-1703）

11.Short-course radiotherapy based total neoadjuvant therapy combined with PD-1 inhibitor for locally advanced rectal cancer: Preliminary findings of TORCH（2023ESMO 601P）
短程放疗为基础的全程新辅助治疗联合PD-1抑制剂治疗局部晚期直肠癌：TORCH研究初步结果

12.Chen, G., et al., Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol, 2023. 8(5): p. 422-431.
新辅助PD-1抑制剂信迪利单抗治疗错配修复缺陷局部晚期直肠癌：一项开放标签单中心2期研究

13.Guzmán Y, Ríos J, Paredes J, et al. Time Interval Between the End of Neoadjuvant Therapy and Elective Resection of Locally Advanced Rectal Cancer in the CRONOS Study. JAMA Surg. 2023;158(9):910-919.
CRONOS研究局部晚期直肠癌患者新辅助治疗末和选择性切除的时间间隔
 
结直肠癌辅助治疗
1.Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial（2023ESMO LBA29）
结直肠癌标准辅助治疗后阿司匹林的作用（ASCOLT）：一项国际、Ⅲ期、随机、安慰剂对照研究

2. Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A multicenter randomized phase II trial (PRODIGE 43 - PACHA-01).（2023ASCO 3515PD）
肝脏复发高危患者结直肠癌肝转移切除术后肝动脉化疗：一项多中心随机Ⅱ期研究（PRODIGE 43 - PACHA-01）

3. Adjuvant systemic chemotherapy with or without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastases resection (HARVEST): A prospective, randomized controlled trial.（2023ASCO 3516PD）
结直肠癌肝转移切除术后辅助系统化疗伴或不伴肝动脉输注氟尿苷（HARVEST）：一项前瞻性随机对照研究

4.Gallois, C., et al., Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials. J Clin Oncol, 2023. 41(4): p. 803-815.
Ⅲ期结肠癌患者早期治疗和奥沙利铂停药的影响：ACCENT/IDEA 11项辅助治疗研究汇总分析

5.Prognostic value of KRAS and BRAF mutations in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: An ACCENT/IDEA pooled analysis of 7 trials（2023ESMO Oral553）
KRAS和BRAF突变在微卫星稳定（MSS）和不稳定（MSI）Ⅲ期结肠癌患者中的预后价值：ACCENT/IDEA 7项研究的汇总分析
 
MRD在结直肠癌围术期的应用
1. Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan.（2023 ASCO 3521）
循环肿瘤DNA动态变化作为根治性切除结直肠癌患者复发早期预测标志物：CIRCULATE-Japan 中GALAXY研究更新结果

2.Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program.（2023 ASCO 3522）
结直肠癌（CRC）监测中阳性ctDNA为基础的微小残留病分析和未诊断的同时性影像学复发的相关性：MD Anderson INTERCEPT项目结果

3.Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC): An updated 24 months (mos) disease free survival (DFS) analysis from GALAXY study (CIRCULATE-Japan)（2023ESMO MO558）
循环肿瘤（ct）DNA作为切除结直肠癌（CRC）患者的预后生物标志物：GALAXY研究（CIRCULATE-Japan）更新24个月无病生存期（DFS）分析

4.The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients（2023ESMO LBA28）
PEGASUS研究：Ⅲ期及高危Ⅱ期结肠癌患者的术后液体活检指导治疗

5.Kotani D, Oki E, Nakamura Y, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023;29(1):127-134. doi:10.1038/s41591-022-02115-4
结直肠癌患者分子残留病和辅助化疗疗效
 
 
肠癌内科治疗
免疫治疗
一线治疗
1.  FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study（2023ASCO Oral3500）
FOLFOXIRI联合贝伐珠单抗和阿替利珠单抗作为不可切除转移性结直肠癌（mCRC）的初始治疗：Ⅱ期随机AtezoTRIBE研究的更新和总生存结果

2.Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study（2023ESMO LBA32）
帕博利珠单抗对比化疗治疗高度微卫星不稳定（MSI-H）/错配修复缺陷（dMMR）转移性结直肠癌（mCRC）：随机Ⅲ期KEYNOTE-177研究5年随访结果

3.First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.（2023ASCO 3550P）
一线纳武利尤单抗+伊匹木单抗治疗高度微卫星不稳定/错配修复缺陷（MSI-H/dMMR）转移性结直肠癌（mCRC）患者：CheckMate 142研究的64个月随访结果

4.Updated results and biomarker analyses from the phase 2 trial (BBCAPX study) of sintilimab plus bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.（2023ASCO 2606P）
信迪利单抗联合贝伐珠单抗和CapeOx一线治疗RAS突变、微卫星稳定、不可切除转移性结直肠癌2期研究（BBCAPX研究）的更新结果和生物标志物分析

5. Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO（2023ASCO 3575P）
改良FOLFOXIRI联合西妥昔单抗和Avelumab作为RAS野生型不可切除转移性结直肠癌初始治疗：GONO Ⅱ期AVETRIC研究结果

6.Thibaudin M, Fumet JD, Chibaudel B, et al. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial. Nat Med. 2023;29(8):2087-2098.
度伐利尤单抗+Tremelimumab+化疗一线治疗RAS突变转移性结直肠癌：一项1b/2期研究
 
二线及以上
1. Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC) （WCGIC LBA4）
多功能CTLA-4抑制剂Botensilimab（BOT）联合PD-1抑制剂Balstilimab（BAL）治疗转移性经多线治疗微卫星稳定结直肠癌（MSS CRC）的扩展1期研究结果

2. Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study（WCGIC LBA5）
仑伐替尼联合帕博利珠单抗对比标准治疗用于经治转移性结直肠癌（mCRC）：3期LEAP-017研究

3. A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab in patients with MSS/pMMR metastatic colorectal cancer（2023ESMO MO556）
信迪利单抗联合西达本胺伴或不伴贝伐珠单抗治疗微卫星稳定/错配修复完整（MSS/pMMR）转移性结直肠癌患者的Ⅱ期研究

4. Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors（2023ESMO 1057P）
替雷利珠单抗（TIS）单药治疗经治局部晚期、不可切除或转移性高度微卫星不稳定（MSI-H）或错配修复缺陷（dMMR）实体瘤的Ⅱ期研究长期随访结果

5. Fakih, M., et al., Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol, 2023.
瑞戈非尼，伊匹木单抗和纳武利尤单抗治疗化疗后疾病进展的微卫星稳定结直肠癌：一项1期非随机临床研究

6. Taïeb J, Bouche O, André T, et al. Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. JAMA Oncol. 2023;9(10):1356-1363.
Avelumab对比标准二线化疗治疗微卫星不稳定转移性结直肠癌患者：一项随机临床研究
 
靶向治疗
   HER2
1.  Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC):Primary results from the multicenter, randomized, phase 2 DESTINYCRC02 study.（2023ASCO Oral3501）
德曲妥珠单抗（T-DXd）治疗HER2过表达/扩增（HER2+）转移性结直肠癌（mCRC）患者：多中心2期DESTINY CRC02研究的初步结果

2.  Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER（2023ESMO Oral551）
MOUNTAINEER研究中基线分子异常对于图卡替尼（TUC）联合曲妥珠单抗（Tras）治疗HER2+、RAS野生型转移性结直肠癌（mCRC）患者疗效的影响
 
  BRAF V600E
1.  VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer.（2023ASCO 3596P/2023SMO 623P）
VIC方案（维莫非尼/伊立替康/西妥昔单抗）对比贝伐珠单抗联合化疗作为BRAF V600E突变晚期结直肠癌一线治疗

2.  Tolerability and safety of vemurafenib, cetuximab combined with camrelizumab for BRAF V600E-mutated /MSS metastatic colorectal cancer（2023SMO 624P）
维莫非尼+西妥昔单抗+卡瑞利珠单抗治疗BRAF V600E突变/微卫星稳定（MSS）转移性结直肠癌的耐受性和安全性

3.  Tian, J., et al., Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial. Nat Med, 2023. 29(2): p. 458-466
BRAF（V600E）结直肠癌中PD-1、BRAF和MEK的联合抑制：一项2期研究

4.  Stintzing S, Heinrich K, Tougeron D, et al. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study [published correction appears in J Clin Oncol. 2023 Sep 12;:JCO2301858]. J Clin Oncol. 2023;41(25):4143-4153.
FOLFOXIRI联合西妥昔单抗或贝伐珠单抗作为BRAFV600E突变转移性结直肠癌的一线治疗：随机Ⅱ期FIRE-4.5（AIO KRK0116）研究
 
  KRAS G12C
1.  Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;388(1):44-54. doi:10.1056/NEJMoa2212419（NEJM）
Adagrasib±西妥昔单抗治疗KRAS G12C突变结直肠癌

2.  Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC): Analysis of tumor biomarkers and genomic alterations（2023ESMO Oral549）
Adagrasib±西妥昔单抗治疗KRAS G12C突变结直肠癌患者：肿瘤生物标志物和基因组异常分析

3.  Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study（2023ESMO Oral550）
D-1553联合西妥昔单抗治疗KRAS G12C突变结直肠癌（CRC）的安全性和疗效：一项Ⅱ期研究

4.  Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study（2023ESMO LBA10）
Sotorasib联合帕尼单抗对比标准治疗用于化疗难治KRAS G12C突变转移性结直肠癌（mCRC）：CodeBreaK 300 Ⅲ期研究
 
   EGFR/VEGFR
1.  Watanabe J, Muro K, Shitara K, et al. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial [published correction appears in JAMA. 2023 Jun 27;329(24):2196]. JAMA. 2023;329(15):1271-1282.
标准一线化疗联合帕尼单抗对比贝伐珠单抗治疗RAS野生型左半转移性结直肠癌的总生存：一项随机临床研究

2.  Stahler A, Hoppe B, Na IK, et al. Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212). J Clin Oncol. 2023;41(16):2975-2987.
共识分子亚型作为氟尿嘧啶和亚叶酸伴或不伴帕尼单抗作为RAS野生型转移性结直肠癌维持治疗的生物标志物（PanaMa, AIO KRK 0212）

3.  Rechallenge with EGFR inhibitors in ctDNA RAS/BRAF wild type refractory metastatic colorectal cancer: Individual patients’ data pooled analysis from 4 phase II trials（2023ESMO MO559）
ctDNA RAS/BRAF野生型难治性转移性结直肠癌的EGFR抑制剂再挑战：4项Ⅱ期研究的个体患者数据汇总分析

4.  Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients(pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): First results of the randomised phase II PANIRINOX-UCGI28 study（2023ESMO LBA30）
帕尼单抗（P）+FOLFIRINOX或mFOLFOX6治疗循环DNA（cirDNA）RAS/BRAF野生型（WT）不可切除转移性结直肠癌（mCRC）患者：随机Ⅱ期PANIRINOX-UCGI28研究的初步结果
 
化疗
1.  Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.（2023ASCO-GI Oral4/N Engl J Med. 2023;388(18):1657-1667.）
曲氟尿苷替匹嘧啶（TAS-102）联合贝伐珠单抗三线治疗难治性转移性结直肠癌：3期随机SUNLIGHT研究

2.  Health‑related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial （WCGIC Oral9）
曲氟尿苷替匹嘧啶（TAS-102）联合贝伐珠单抗治疗难治性转移性结直肠癌的健康相关生活质量：3期SUNLIGHT研究分析

3.  Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: a post-hoc analysis of the phase 3 SUNLIGHT trial（2023 ESMO 613P）
既往应用抗VEGF药物对难治性结直肠癌患者总生存的影响：3期SUNLIGHT研究的事后分析

4.  Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: a post-hoc analysis of the phase 3 SUNLIGHT trial（2023 ESMO 614P）
KRAS G12C突变对于难治性转移性结直肠癌患者总生存的影响：3期SUNLIGHT研究的事后分析

5.  Maintenance with 5FU/LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept until progression in older patients (pts) in 2nd line metastatic colorectal cancer (mCRC): The randomized AFEMA trial（2023ESMO MO560）
老年转移性结直肠癌（mCRC）患者二线治疗中FOLFIRI-Aflibercept诱导治疗后5FU/LV-Aflibercept维持治疗对比FOLFIRI-Aflibercept持续治疗直至进展：随机AFEMA研究
 
NeoRAS
1.  NeoRAS wild-type metastatic colorectal cancer in the SCRUM-Japan GOZILA study（2023ASCO Oral3506）
SCRUM-Japan GOZILA研究中NeoRAS野生型转移性结直肠癌

2.  Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.（2023ASCO Oral3507）
Ⅲ期FIRE-4研究（AIO KRK-0114）：基线液体活检结果对于组织RAS野生型mCRC患者一线FOLFIRI/西妥昔单抗疗效的影响

3.  Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.（2023ASCO Oral3508）
帕尼单抗治疗左半、MSS/MSI-L、RAS/BRAF野生型患者的疗效：Ⅲ期PARADIGM研究的生物标志物分析
 
其他
   肝转移
1.  Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in RAS wild-type patients with initially unresectable colorectal liver metastases: The TRICE randomized clinical trial（2023ESMO MO554）
西妥昔单抗联合FOLFOXIRI对比西妥昔单抗联合FOLFOX治疗RAS野生型初始不可切除结直肠癌肝转移患者：TRICE随机临床研究

2.  First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group（2023ESMO LBA27、Lancet Oncol. 2023;24(7):757-771)
初始不可切除直肠癌肝转移（CRLM）患者的一线系统治疗：荷兰结直肠癌组Ⅲ期CAIRO5研究的总生存
 
   腹膜转移
1.15-month safety and efficacy data after intraperitoneal treatment with 224Radium-labelled microparticles after CRS-HIPEC for peritoneal metastasis from colorectal cancer.（2023ASCO 3518PD）
肿瘤细胞减灭术和腹腔热灌注化疗（CRS-HIPEC）后224镭标记微粒腹腔内治疗用于结直肠癌腹膜转移患者的15个月安全性和疗效数据

Prophylactic hyperthermic intraperitoneal chemotherapy in T4 colorectal cancer: Can it improve the oncologic prognosis?（2023ASCO 3619P）
预防性腹腔热灌注化疗治疗T4结直肠癌：可以改善肿瘤预后吗？
 
直肠癌围术期治疗
化放疗
1.  Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)（2023ASCO-GI Oral7）
NRG-GI002的长期结果：全程新辅助治疗（TNT）用于局部晚期直肠癌（LARC）的Ⅱ期临床研究平台

2. Preoperative Chemotherapy with Selective Chemoradiation versus Chemoradiation for Locally Advanced Rectal Cancer:The PROSPECT Trial (Alliance N1048)（2023ASCO LBA2）
术前化疗联合选择性化放疗对比常规化放疗治疗局部晚期直肠癌：PROSPECT研究（Alliance N1048）

3. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.（2023ASCO LBA3504）
mFOLFIRINOX全程新辅助治疗对比术前化放疗治疗局部晚期直肠癌患者：UNICANCER GI研究PRODIGE 23 Ⅲ期研究的7年结果

4.Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): Final results of a phase III trial（2023ESMO LBA26）
CAPOX新辅助化疗对比化放疗治疗直肠系膜筋膜未受累的局部晚期直肠癌：CONVERT Ⅲ期研究的最终结果

5.Neoadjuvant chemotherapy (NAC) followed by total mesorectal excision (TME) and adjuvant chemotherapy versus TME followed by adjuvant chemotherapy in very low-lying clinical (c) T3 rectal cancer (NAIR): A multicenter, randomized, open-label, phase 2/3 trial.（2023ASCO 3519PD）
新辅助化疗（NAC）后全系膜切除（TME）和辅助化疗对比TME后辅助化疗用于极低位临床（c）T3直肠癌（NAIR）：一项多中心、随机、开放标签、2/3期研究
6. Ruppert R, Junginger T, Kube R, et al. Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer: Final Report of the OCUM Study. J Clin Oncol. 2023;41(24):4025-4034.
风险适应性新辅助化放疗治疗直肠癌：OCUM研究的最终报告

7.Sustained organ preservation in patients with rectal cancer treated with total neoadjuvant therapy: Long-term results of the OPRA trial.（2023ASCO 3520PD）
接受全程新辅助治疗的直肠癌患者的持续器官保留：OPRA研究的长期结果

8.Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial.（2023ASCO Oral3505）
新辅助mFOLFOX6伴或不伴放疗对比氟尿嘧啶联合放疗治疗局部晚期直肠癌的长期结局：一项多中心随机Ⅲ期研究

9. Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long-course chemoradiation versus short-course radiation therapy.（2023ASCO-GI  Rapid Abstractl0）
直肠癌的器官保留和全程新辅助治疗：研究长程化放疗对比短程放疗

10.Do nonoperative modality (NOM) treatments of rectal cancer compromise the chance of cure? Final surgical salvage results from OPERA phase 3 randomised trial (NCT02505750)（2023ASCO-GI Oral6）
非手术模式（NOM）治疗用于直肠癌患者是否损害根治机会？OPERA 3期随机试验（NCT02505750）的最终手术挽救结果
 
免疫
1. Chen, G., et al., Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol, 2023. 8(5): p. 422-431.
新辅助PD-1抑制剂信迪利单抗治疗错配修复缺陷局部晚期直肠癌：一项开放标签、单中心2期研究

2. Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: A randomized phase III trial (UNION)（2023ESMO LBA25）
新辅助短程放疗后卡瑞利珠单抗联合化疗对比长程化放疗后化疗治疗局部晚期直肠癌：一项随机Ⅲ期研究（UNION）

3.The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)（2023ESMO 595P）
DUREC研究：度伐利尤单抗联合全程新辅助治疗用于局部晚期直肠癌——一项多中心、单臂、Ⅱ期研究（GEMCAD-1703）

4.Short-course radiotherapy based total neoadjuvant therapy combined with PD-1 inhibitor for locally advanced rectal cancer: Preliminary findings of TORCH（2023ESMO 601P）
短程放疗为基础的全程新辅助治疗联合PD-1抑制剂治疗局部晚期直肠癌：TORCH研究的初步结果
 
其他
手术
1.Guzmán Y, Ríos J, Paredes J, et al. Time Interval Between the End of Neoadjuvant Therapy and Elective Resection of Locally Advanced Rectal Cancer in the CRONOS Study. JAMA Surg. 2023;158(9):910-919.
CRONOS研究局部晚期直肠癌新辅助治疗末和选择性切除的时间间隔

2.El Sissy C, Kirilovsky A, Lagorce Pagès C, et al. International Validation of the Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy [published online ahead of print, 2023 Oct 3]. J Clin Oncol. 2023;JCO2300586.
直肠癌患者行等待观察策略后免疫评分活检的国际验证

Session1：前列腺癌研究进展局限期
（2023 ESMO）1764O-Timing of radiotherapy (RT) after radical prostatectomy  (RP):Final  results  of  RADICALS  RT  randomised  controlled  trial
根治性前列腺切除术（RP）后放疗（RT）的时机：RADICALS RT随机对照试验的最终结果

（2023 ESMO）LBA13 - Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)
[177Lu]Lu-PSMA-617治疗紫杉烷初治的转移性去势抵抗性前列腺癌患者的Ⅲ期临床试验（PSMAfore）

（2023 ASCO）5002-Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.
完成RT的局部前列腺癌患者6个月内PSA最低值(PSAn)≥0.1 ng/ml的预后影响:来自ICECAP合作的随机试验的个体患者数据分析

 晚期
（2023 ESMO-ASIA）255O-Darolutamide in combination with androgen-deprivation therapy and docetaxel in Chinese patients with metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS study
达罗他胺与雄激素剥夺疗法和多西他赛联合应用于转移性激素敏感型前列腺癌3期ARASENS研究中国亚组数据分析

（2023 ASCO-GU）332-Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR)
DEAR研究：真实世界研究中比较达罗他胺、恩扎卢胺和阿帕他胺治疗非转移性去势抵抗性前列腺癌

（2023 ASCO）5097-Comparative Real-world Evidence on Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients in the United States (DEAR)
达罗他胺、恩扎卢胺和阿帕他胺治疗非转移性去势抵抗性前列腺癌患者的真实世界证据对比 (DEAR)

（2023 ASCO-GU）73-Time interval between radium‑223 (223Ra) therapy and Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) treatment and outcomes in the RALU study
RALU 研究：镭-223(223Ra) 与镥-177-前列腺特异性膜抗原 (177Lu-PSMA) 治疗的治疗间期和临床结局

（2023 ESMO）1816P-Combination treatment with radium-223 (223Ra) and enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study
REASSURE研究：镭-223(223Ra)联合恩扎卢胺治疗转移性去势抵抗性前列腺癌(mCRPC)患者

（2023 ASCO）LBA5000-Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.
对新发、低瘤负荷、转移性的去势敏感性前列腺癌(mCSPC)患者进行前列腺放疗:2x2设计的3期随机临床试验PEACE-1研究结果

（2023 ESMO）LBA86 -Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial
一项随机、结果自适应、生物标志物驱动的平台试验ProBio：雄激素受体信号通路抑制剂或紫杉烷用于转移性去势抵抗性前列腺癌患者的直接比较

（2023 ASCO GU）LBA16-Final overall survival (OS) in PROpel: abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).
PROpel中的最终总生存期（OS）：阿比特龙联合奥拉帕尼与阿比特龙和安慰剂作为转移性去势抵抗性前列腺癌（mCRPC）的一线（1L）治疗

（2023 ASCO）5003-Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first-line (1L) treatment stratified by BRCA status.
按照BRCA状态分层，接受一线治疗的转移性去势抵抗性前列腺癌（mCRPC）患者中体细胞/种系同源重组修复（HRR）突变的存在和结局

（2023 ASCO）5004-TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.
TALAPRO-2：talazoparib（TALA）+ 恩扎卢胺（ENZA）vs 安慰剂（PBO）+ ENZA作为一线治疗在转移性去势抵抗性前列腺癌（mCRPC）携带同源重组修复（HRR）基因改变的患者的Ⅲ期研究
 
Session2：尿路上皮癌研究进展
 围术期治疗
ASCO LBA4507-Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC)as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC):Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.
GETUG / AFU V05 VESPER试验：剂量密集甲氨蝶呤、长春碱、多柔比星和顺铂（dd-MVAC）新辅助化疗在肌层浸润性膀胱癌（MIBC）的应用，患者5年总生存（OS）数据分析
ASCO GU  LBA443Extended follow-up results from the CheckMate 274 trial.
CheckMate 274 试验的延长随访结果

 一线治疗
ESMO LBA6-EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
EV-302/KEYNOTE-A39：Enfortumab Vedotin联合帕博利珠单抗（EV+P）对比化疗（Chemo）治疗既往未接受治疗的局部晚期转移性尿路上皮癌（la/mUC）患者的开放标签、随机3期研究

ESMO LBA7-Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable ormetastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial
纳武利尤单抗联合吉西他滨-顺铂vs吉西他滨-顺铂单药治疗既往未接受治疗的不可切除或转移性尿路上皮癌患者：Ⅲ期CheckMate 901试验

ASCO GU  LBA440-Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study.
阿替利珠单抗+铂/吉西他滨对比安慰剂+铂/吉西他滨用于一线治疗局部晚期或转移性尿路上皮癌（mUC）患者：随机3期IMvigor130研究的最终OS结果

ASCO GU  LBA441-Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.
阿替利珠单抗单药对比化疗一线治疗局部晚期或转移性尿路上皮癌（mUC）患者：随机3期IMvigor130研究的最终OS结果

 后线治疗
ASCO LBA4619-Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy(chemo) in patients (pts) with advanced or metastatic urothelial cancer(mUC) with select fibroblast growth factor receptor alterations (FGFRalt).
3期THOR研究：Erdafitinib vs化疗治疗选择性FGFR改变的晚期或转移性尿路上皮癌（mUC）患者的结果

ESMO LBA102THOR-2 cohort1: Results of erdafitinib(ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk nonemuscle-invasive bladder cancer (HR NMIBC) with selectfibroblast growth factor receptor alterations (FGFRALT) whoreceived prior bacillus calmette-guérin (BCG) treatment
THOR-2队列1：erdafitinib（ERDA） vs 膀胱内化疗（chemo）在接受过卡介苗（BCG）治疗发生选择性成纤维细胞生长因子受体改变（FGFRALT）的高危非肌层浸润性膀胱癌(HR NMIBC)患者中的结果比较

ASCO GU  LBA442-Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette–Guérin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial.
帕博利珠单抗单药治疗对卡介苗无应答的高危非肌层浸润性膀胱癌（HR NMIBC）：2期KEYNOTE-057试验的队列B的结果
 
Session3：肾癌研究进展诊断
（2023 ASCO GU）LBA602-Results from phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON).
89 Zr-DFO-girentuximab用于肾透明细胞癌PET/CT成像的III期研究（ZIRCON）结果

 辅助治疗
（2023 ASCO）4506-Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.
肾切除术后复发风险高的局限性肾细胞癌患者的辅助nivolumab + ipilimumab vs安慰剂： 3期CheckMate 914（A组）试验的亚组分析

 一线治疗
（2023 ESMO）1882O - RENOTORCH: Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced renal-cell carcinoma (RCC) - A randomized, open-label, phase III study
RENOTORCH：特瑞普利单抗联合阿昔替尼对比舒尼替尼一线治疗晚期肾癌：一项随机、开放标签、III期临床研究

 后线治疗
（2023 ESMO）LBA88 - Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label phase 3 LITESPARK-005 study
LITESPARK-005研究：贝组替凡对比依维莫司在既往接受过治疗的晚期肾透明细胞癌(ccRCC)患者中的研究：一项随机、开放标签、Ⅲ期临床研究

（2023 ASCO GU）607-Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial.
随机II期BIONIKK试验：转移性透明细胞肾细胞癌（mRCC）患者的二线治疗的总生存期（OS）和疗效

（2023 ASCO）LBA4500-Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.
阿特利珠单抗联合卡博替尼 vs卡博替尼单药用于既往免疫检查点抑制剂(ICI)治疗后进展的转移性肾细胞癌(RCC)：3期、随机、开放标签的CONTACT-03研究的初次PFS分析结果

Session1：早期乳腺癌诊疗研究进展

主题1：HR+早期乳腺癌新辅助及辅助治疗研究进展
 
CDK4/6抑制剂辅助强化治疗  

阿贝西利联合内分泌治疗辅助治疗HR+/HER2-、高危早期乳腺癌：monarchE预设总生存期中期分析的结果，包括5年疗效结局Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes（2023ESMO LBA17）
 
阿贝西利联合内分泌治疗辅助治疗HR+/HER2- 淋巴结阳性高危早期乳腺癌: monarchE研究按年龄分层的疗效和安全性结局Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive，high-risk early breast cancer (EBC) (2023ASCO 501)

monarchE研究患者报告的长期结局：阿贝西利联合内分泌治疗辅助治疗淋巴结阳性、高危、HR+/HER2- 早期乳腺癌Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy for adjuvant HR+, HER2-, node-positive, high-risk, early breast cancer (EBC) （2023ESMO BC 93MO）

HR+/HER2-早期乳腺癌患者中瑞波西利联合非甾体类芳香化酶抑制剂的疗效评价：Ⅲ期NATALEE研究关键亚组的无浸润性性疾病生存期 (iDFS)结局Invasive disease–free survival (iDFS) across key subgroups from the Phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC) （2023ESMO LBA23）
 
Ⅲ期NATALEE试验：瑞波西利+内分泌治疗辅助治疗HR+/HER2- 早期乳腺癌Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer（2023ASCO LBA500）
 
瑞波西利+非甾体芳香化酶抑制剂（NSAI）辅助治疗HR+/HER2-早期乳腺癌患者：NATALEE试验的最终无浸润性疾病生存（iDFS）分析Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial（2023SABCS GS03-03）
 
哌柏西利辅助治疗ER+ 乳腺癌：PALLAS试验（ABCSG-42/AFT-05/PrE0109/BIG-14-13）ⅡA期队列的预设分析结局Adjuvant Palbociclib for ER+ Breast Cancer (PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A Preplanned Analysis of the Stage IIA Cohort（2023ASCO 摘要更新：390216）
 
（新）辅助免疫治疗

KEYNOTE-756：在高危ER+/HER2-早期乳腺癌患者中进行的新辅助帕博利珠单抗/安慰剂+化疗，序贯辅助帕博利珠单抗/安慰剂+内分泌治疗的Ⅲ期研究KEYNOTE-756: Phase 3 study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2- breast cancer（2023ESMO LBA21）

在高风险ER+/HER2-原发性乳腺癌患者中比较纳武利尤单抗+化疗 vs 安慰剂+化疗新辅助治疗序贯辅助内分泌治疗±纳武利尤单抗的随机、双盲试验A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2- primary breast cancer (BC) （2023ESMO LBA20）


主题2：早期TNBC免疫治疗研究进展
 
3期KEYNOTE-522研究：新辅助帕博利珠单抗或安慰剂+化疗后辅助帕博利珠单抗或安慰剂治疗早期TNBC的无事件生存期（EFS）数据更新Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study(2023SABCS LBO1-01)

帕博丽珠单抗/安慰剂联合化疗，序贯帕博丽珠单抗/安慰剂治疗早期TNBC：Ⅲ期KEYNOTE-522研究更新的无事件生存期 (EFS) 结局Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase 3 KEYNOTE-522 study（2023ESMO LBA18）

APTneo Michelangelo研究：加或不加阿替利珠单抗新辅助治疗HER2+早期高危和局晚期乳腺癌病理完全缓解（pCR）的疗效Pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2-positive, early high-risk and locally advanced breast cancer: APTneo Michelangelo randomized trial（2023SABCS LBO1-02）

新辅助紫杉醇/卡铂±阿替利珠单抗序贯蒽环类药物辅助治疗高风险TNBC患者：NeoTRIP Michelangelo随机研究的EFS分析结局Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study(2023ESMO LBA19)

ALEXANDRA/IMpassion030 Ⅲ期试验中期分析：Ⅱ期和Ⅲ期TNBC辅助化疗加用阿替利珠单抗可能无法改善疗效Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial(2023SABCS GS01-03)

早期TNBC患者阿替利珠单抗与肿瘤微环境的相关性：IMpassion031试验的探索性生物标志物分析Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer (eTNBC): Exploratory biomarker analysis from IMpassion031（2023ESMO 2232O）

评估新辅助阿替利珠单抗联合化疗序贯辅助阿替利珠单抗治疗早期TNBC患者的安慰剂对照随机3期临床研究-IMpassion031试验最终分析Final analysis of the placebo-controlled randomised phase 3 IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)（2023ESMO BC LBA1）

通过检测外周免疫细胞的RNA表达水平（微创液体活检），预测入组GeparNuevo试验的TNBC患者的治疗反应、生存期和免疫相关不良事件RNA expression levels from peripheral immune cells, a minimally invasive liquid biopsy source to predict response to therapy, survival and immune-related adverse events in patients with triple negative breast cancer enrolled in the GeparNuevo trial （2023ASCO 1011）
 
Session2：晚期乳腺癌诊疗研究进展

HR+晚期乳腺癌解救内分泌治疗进展

PARSIFAL-LONG：对PARSIFAL研究中接受氟维司群+哌柏西利 vs 来曲唑+哌柏西利治疗的HR+/HER2-晚期乳腺癌患者的延长随访PARSIFAL-LONG: Extended follow-up of hormone receptor-positive /HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study (2023SABCS RF01-03)
 
HR+/HER2- 晚期乳腺癌患者选择CDK4/6抑制剂最佳治疗时机的3期 SONIA 试验 (BOOG 2017-03) 的主要结局分析Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)(2023ASCO LBA1000)
 
随机Ⅲ期LEONARDA-1研究：lerociclib+氟维司群治疗既往内分泌治疗后进展的HR+/HER2- 局晚期或转移性乳腺癌LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy(2023ASCO 摘要号：1017| Poster Bd #: 238) 研究PI徐兵河教授
 
二线内分泌治疗联合或不联合哌柏西利维持治疗HR+/HER2- 晚期乳腺癌：PALMIRA试验Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial(2023ASCO 1001)

Capivasertib联合氟维司群用于芳香化酶抑制剂耐药的HR+/HER2- 晚期乳腺癌：Ⅲ期 CAPItello-291 试验的亚组分析结果Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): subgroup analyses from the Phase 3 CAPItello-291 trial（2023ESMO BC 187O）

EMERALD 试验：口服 elacestrant  vs 标准内分泌治疗在ER+/HER2- 晚期或转移性乳腺癌中的患者报告结局EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2_ advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy（2023ESMO BC 188O）

Imlunestrant联合或不联合依维莫司或阿培利司治疗ER+/HER2-晚期乳腺癌：1a/B期EMBER研究的结果Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase 1a/b EMBER study(2023ESMO 383MO)

OP-1250[兼具完全雌激素受体拮抗剂(CERAN)和选择性雌激素受体降解剂(SERD)活性的口服小分子药物]治疗晚期或转移性ER+/HER2-乳腺癌患者的Ⅰ/Ⅱ期研究的更新结果Updated results from the phase 1/2 study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD ) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer(2023ESMO 382MO)

氟维司群 vs 阿那曲唑在未经内分泌治疗的激素受体阳性晚期乳腺癌中的最终总生存期分析 (FALCON) Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast cancer (FALCON) （2023ESMO 384MO）

HER2+晚期乳腺癌解救治疗研究进展

Zanidatamab+哌柏西利+氟维司群治疗HER2+/HR+转移性乳腺癌的Ⅱa期研究主要结果Primary results from a phase 2a study of zanidatamab (zani) + palbociclib (palbo) + fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC)（2023SABCS LBO1-04

HER2CLIMB-02：图卡替尼和恩美曲妥珠单抗用于经治HER2阳性转移性乳腺癌的随机、双盲、3期试验HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated her2-positive metastatic breast cancer(2023SABCS GS01-10)

RF02-04 JCOG1607 HERB TEA研究：一项比较恩美曲妥珠单抗与曲妥珠单抗、帕妥珠单抗和多西他赛治疗转移性HER2阳性乳腺癌老年患者的Ⅲ期研究A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with metastatic HER2-positive breast cancer (JCOG1607 HERB TEA study) (2023SABCS RF02-04)

AVIATOR/TBCRC045：评估长春瑞滨+曲妥珠单抗联合或不联合阿维鲁单抗±utomilumab治疗HER2+转移性乳腺癌患者的随机Ⅱ期研究（NCT03414658）AVIATOR/TBCRC045: A randomized phase II study of vinorelbine (N) + trastuzumab (H) alone or combined with avelumab (A) +/- utomilumab (U) in patients (pts) with HER2+ metastatic breast cancer (MBC) (NCT03414658) (2023SABCS RF02-06)

DESTINY-Breast (DB) -01、DB-02和DB-03研究的汇总分析：德曲妥珠单抗治疗伴脑转移的HER2阳性转移性乳腺癌患者A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2-Positive (HER2+) Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03（2023ESMO 377O）

Trastuzumab duocarmazine与医生选择的疗法治疗既往治疗过的 HER2 阳性转移性乳腺癌：Ⅲ期 TULIP 试验的最终结果Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase III TULIP trial（2023ESMO 386MO）

DP303c在既往接受过治疗的HER2阳性晚期实体瘤患者中的多中心、开放标签、剂量递增和扩展研究A multicenter,open-label,dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors（2023ESMO 385MO）（研究PI：张剑教授）

在 HER2 阳性转移性乳腺癌患者中比较T-DXd与医生选择的治疗：随机Ⅲ期DESTINY-Breast02研究中患者报告的结局Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC)（2023ESMO BC 186O）
 
Session3：乳腺癌靶向治疗新疗法研究进展
 
HR+/HER2-乳腺癌

SKB264 (MK-2870)用于既往接受过治疗的HR+/HER2-转移性乳腺癌：一项Ⅰ/Ⅱ期单臂、篮式试验的结果SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): results from a phase I/II, single-arm, basket trial（2023ESMO 380MO）（研究PI：殷咏梅教授）

Datopotamab deruxtecan(Dato-DXd) vs 化疗治疗既往经治的不可手术或转移性HR+/HER2-乳腺癌：Ⅲ期TROPION-Breast01随机试验的主要结果Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised Phase 3 TROPION-Breast01 trial（2023ESMO LBA11 ）

Datopotamab deruxtecan对比化疗治疗无法手术或转移性ER+/HER2-乳腺癌患者：随机3期TROPION-Breast01研究的疗效、安全性和生物标志物结果Randomised phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2- breast cancer: efficacy, safety and biomarker results from TROPION-Breast01(2023SABCS GS02-01)

戈沙妥珠单抗(SG)治疗HR+/HER2- 转移性乳腺癌的Ⅲ期 TROPiCS-02研究的最终总生存期分析Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC)(2023ASCO 1003)

Patritumab deruxtecan (HER3-DXd) 治疗HR+/HER2- 乳腺癌和三阴性乳腺癌：SOLTI TOT-HER3机会窗试验 B 部分的结果Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple negative breast cancer (TNBC): results of part B of SOLTI TOT-HER3 window of opportunity trial (2023ESMO BC 124O)

早期HR+/HER2-乳腺癌中的HER2表达和patritumab deruxtecan(HER3-DXd) 的早期应答：SOLTI-TOT-HER 3试验的相关性分析HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): a correlative analysis from SOLTI-TOT-HER3 trial （2023ESMO BC 3MO）

TNBC

Tinengotinib治疗晚期或转移性HR+/HER2-乳腺癌或TNBC患者的疗效和安全性The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2- breast cancer or TNBC(2023SABCS RF01-07)

Ⅰb/Ⅱ期BEGONIA研究的更新结果：Dato-DXd+度伐利尤单抗一线治疗不可切除局部晚期/转移性TNBC患者Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study（2023ESMO 379MO）

Patritumab deruxtecan (HER3-DXd) 治疗HR+/HER2- 乳腺癌和TNBC：SOLTI TOT-HER3机会窗试验 B 部分的结果Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple negative breast cancer (TNBC): results of part B of SOLTI TOT-HER3 window of opportunity trial (2023ESMO BC 124O)

HER2低表达乳腺癌

DESTINY-Breast08（一项Ⅰb期、开放标签、多中心、剂量扩展研究）：德曲妥珠单抗（T-DXd）联合阿那曲唑或氟维司群治疗HER2低表达、HR+晚期/转移性癌症患者Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08)(2023SABCS RF02-03)

随机、Ⅲ期DESTINY-Breast04研究更新的生存结果：德曲妥珠单抗 vs 医生选择的治疗 (TPC) 治疗HER2低表达不可切除和/或转移性乳腺癌患者Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase 3 DESTINY-Breast04 study（2023ESMO 376O）

在 HER2 低表达不可切除和/或转移性乳腺癌患者中比较德曲妥珠单抗(T-DXd) 与医生选择的治疗：随机、Ⅲ期 DESTINY-Breast04 试验的详细安全性分析结局Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): a detailed safety analysis of the randomized, phase 3 DESTINY-Breast04 trial (2023 ESMO BC 185O)

DESTINY-Breast 04亚组分析：在HER2低表达、雌激素受体表达免疫组织化学为0~10%的转移性乳腺癌患者中比较T-DXd与医生选择的治疗DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC) (2023 ESMO BC 192MO)

HER2阳性乳腺癌

Zanidatamab+哌柏西利+氟维司群治疗HER2+/HR+转移性乳腺癌的Ⅱa期研究主要结果Primary results from a phase 2a study of zanidatamab (zani) + palbociclib (palbo) + fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC)（2023SABCS LBO1-04）

AVIATOR/TBCRC045：评估长春瑞滨+曲妥珠单抗联合或不联合阿维鲁单抗±utomilumab治疗HER2+转移性乳腺癌患者的随机Ⅱ期研究（NCT03414658）AVIATOR/TBCRC045: A randomized phase II study of vinorelbine (N) + trastuzumab (H) alone or combined with avelumab (A) +/- utomilumab (U) in patients (pts) with HER2+ metastatic breast cancer (MBC) (NCT03414658) (2023SABCS RF02-06)

Trastuzumab duocarmazine与医生选择的疗法治疗既往治疗过的 HER2 阳性转移性乳腺癌：Ⅲ期 TULIP 试验的最终结果Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase III TULIP trial（2023ESMO 386MO）

DP303c在既往接受过治疗的HER2阳性晚期实体瘤患者中的多中心、开放标签、剂量递增和扩展研究A multicenter,open-label,dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors（2023ESMO 385MO）（研究PI：张剑教授）

Session1：可切除性食管癌治疗进展
新辅助治疗
1.    Neo-AEGIS(Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction lnternational Study):Final primary outcome analysis（2023ASCO GI 295）

1.Neo-AEGIS（Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction lnternational Study）：最终主要结局分析（2023 ASCO GI 295）
 
辅助治疗
 
1.    ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer（2023ASCO 4000）
1.ATTRACTION-5：纳武利尤单抗联合化疗作为病理学III期（pStage III）胃/胃食管交界部肿瘤（G/GEJ）患者术后辅助治疗的III期研究（2023 ASCO 4000）
 
2.    Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial（2023ASCO 4001）
2.围手术期PD-1抗体特瑞普利单抗联合SOX/XELOX化疗vs.SOX/XELOX单纯治疗局部进展期胃/胃食管交界部肿瘤：一项前瞻性、随机、开放标签、II期试验的结果（2023 ASCO 4001）
 
3.    EORTC 1707 VESTIGE: adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study（2023 WCGIC O-6）
3.EORTC 1707 VESTIGE：术前化疗并手术切除的高复发风险胃食管腺癌（GEA）患者接受辅助免疫治疗（ypN+/R1）——一项开放标签随机对照II期研究（2023 WCGIC O-6）
 
围手术期治疗
1.    Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the first interim analysis of a randomized, phase 3 trial (DRAGON IV)（2023ESMO 1512MO）
1.围手术期卡瑞利珠单抗（C）联合雷莫西尤单抗（R）+化疗（chemo）vs.化疗治疗局部进展期可切除胃/胃食管交界部（G/GEJ）腺癌：一项随机、3期试验（DRAGON IV）的首次中期分析（2023 ESMO 1512 MO）
 
生物标志物
1.R. Kelly et al. Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577（2023WCGIC O-7）
1.新辅助放化疗后切除的食管/胃食管交界部肿瘤接受辅助纳武单抗vs.安慰剂治疗：来自CheckMate 577综合生物标志物分析的首次报告（2023 WCGIC O-7）
 
Session2：晚期食管癌治疗进展
晚期一线
 
MSI-H
1.A Phase Ⅱ study of Nivolumab plus low dose Ipilimumab as 1st line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)（2023ESMO 1513O）
1.纳武利尤单抗联合低剂量伊匹木单抗作为晚期胃/胃食管交界部MSI-H肿瘤患者一线治疗的II期研究：NO LIMIT研究的初步结果（WJOG13320G/CA209-7W7）（2023ESMO 1513O）
 
Claudin18.2
1.    Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+(CLDN18.2+)/ HER2- locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study （2023ASCO GI LBA292）
1.    Zolbetuximab + mFOLFOX6作为claudin-18.2阳性（CLDN18.2+）/HER 2阴性局部进展期（LA）不可切除或转移性胃/胃食管交界部（mG/GEJ）腺癌患者（pts）的一线（1 L）治疗：来自III期SPOTLIGHT研究的主要结果（2023 ASCO GI LBA 292）
 
2.    Updates on Abstract 405736: Zolbetuximab + Capox in 1L Claudin-18.2+ (CLDN18.2+)/HER2− Locally Advanced (LA) or Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Primary Phase 3 Results from Glow  （2023ASCO 405736）
2.    Zolbetuximab+ CAPOX一线治疗Claudin-18.2阳性（CLDN18.2阳性）/HER 2阴性局部进展期（LA）或转移性胃/胃食管交界处（mG/GEJ）腺癌：Glow的主要III期结果（2023 ASCO 405736）
 
HER-2
1.    Pembrolizumab plus Trastuzumab and Chemotherapy for HER2+ Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Survival results from the Phase 3, Randomized, Double-blind, Placebo-controlled KEYNOTE-811 Study（2023ESMO 1511O）
1.    帕博利珠单抗联合曲妥珠单抗+化疗治疗HER 2+转移性胃或胃食管交界处（mG/GEJ）腺癌：来自3期、随机、双盲、安慰剂对照KEYNOTE-811研究的生存结果（2023 ESMO 1511 O）
 
免疫
1.    Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)（2023ASCO GI 286）
2.    Rationale 305：替雷利珠单抗联合化疗vs.安慰剂联合化疗作为晚期胃/胃食管交界处腺癌（GC/GEJC）一线治疗（1 L）的III期研究（2023 ASCO GI 286）
 
3.    Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma(ESCC): 29-month (mo) follow-up from CheckMate 648（2023ASCO GI 8）
3.纳武利尤单抗（NIVO）联合化疗（chemo）vs.纳武利尤单抗联合伊匹木单抗（IPI）vs.化疗作为晚期食管鳞状细胞癌（ESCC）的一线（1 L）治疗：CheckMate 648的29个月（mo）随访数据（2023 ASCO GI 8）
 
4.    Nivolumab(NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L)treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-vear follow-up from CheckMate 649（2023ASCO GI 291）
3.纳武利尤单抗（NIVO）+化疗（chemo）vs.chemo作为晚期胃/胃食管交界部/食管腺癌的一线治疗（GC/GEJC/EAC）：CheckMate 649的3年随访数据
 
晚期二线及以上治疗
1.    INTEGRATE Ⅱa: A randomised, double-blind, phase Ⅲ study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG)（2023ASCO GI LBA294）
1.INTEGRATE Ⅱa：由澳大利亚胃肠试验组（AGITG）主导的瑞戈非尼vs.安慰剂治疗难治性晚期胃食管癌（AGOC）的随机、双盲、Ⅲ期研究（2023ASCO GI LBA294）
Session3：生物标志物指导下的食管癌精准治疗
1.Comparative analysis of the molecular profile and tumor immune microenvironment (TIME) of human epidermal growth factor receptor 2(HER2) low (L)- versus high (H)-expressing gastroesophageal cancers (GEC)（2023ASCO GI 287）
1.人表皮生长因子受体2（HER2）低（L）vs.高（H）表达胃食管癌（GEC）分子谱和肿瘤免疫微环境（TIME）的比较分析（2023ASCO GI 287）

Session 1 头颈部鳞癌免疫治疗进展
免疫疗法在复发/转移性头颈部鳞癌中的探索与思考
免疫单药
II期ADJORL1研究：头颈部癌鳞状细胞癌（HNSCC）挽救性手术后的纳武利尤单抗辅助免疫治疗的疗效和毒性Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (HNSCC): phase 2 trial evaluating the efficacy and the toxicity of Nivolumab (ADJORL1)（2023 ESMO 855MO）
 
免疫联合靶向
INTERLINK-1：西妥昔单抗（CTX）± monalizumab（M）对应用含铂化疗进展的免疫检查点抑制剂经治的R/M HNSCC患者的III期研究INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/ metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)（2023 ESMO：854O）
 
免疫联合化疗
卡瑞利珠单抗联合多西他赛、顺铂和卡培他滨诱导治疗晚期下咽癌的抗肿瘤活性和安全性Antitumor activity and safety profile of camrelizumab plus docetaxel, cisplatin, and capecitabine for induction therapy in advanced stage hypopharyngeal carcinoma（2023 ESMO：934P）
作者：周梁（复旦大学附属眼耳鼻喉科医院）

评估度伐利尤单抗联合每周紫杉醇-卡铂在不符合顺铂治疗条件的复发/转移头颈鳞状细胞癌（R/M SCCHN）患者一线的疗效和安全性的多中心II期FRAIL-IMMUNE试验的结果Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies（2023 ASCO：6003）
 
其他
一项对比医生选择的标准治疗与三联节拍疗法作为头颈部肿瘤二线治疗疗效的Ⅲ期随机研究（CRSF 2021-HN-001）Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001)（2023 ASCO：LBA6004）
 
局晚期头颈部鳞癌的新辅助免疫治疗
1.       诱导化疗联合特瑞普利单抗用于可切除局部晚期喉癌/下咽癌患者的保喉治疗的Ⅱ期临床试验（INSIGHT研究）Induction chemotherapy and toripalimab for larynx preservation in resectable locally advanced laryngeal/hypopharyngeal carcinoma: Preliminary results of INSIGHT study（2023 ASCO：6068P）报告人：复旦大学附属肿瘤医院 区晓敏

2.       特瑞普利单抗联合多西他赛和顺铂诱导治疗局部晚期下咽鳞状细胞癌（HPSCC）：一项单臂II期临床试验Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial（2023 ASCO：6070P）报告人：北京协和医院 白春梅

3.     新辅助免疫化疗治疗局部晚期喉和下咽鳞状细胞癌：一项单臂2期临床试验Neoadjuvant chemoimmunotherapy for the treatment of locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: A single-arm phase 2 clinical trial（2023 ASCO：6077P）报告人：中山大学肿瘤防治中心 陈艳峰

4.     新辅助低剂量放疗、替雷利珠单抗联合白蛋白结合紫杉醇和顺铂治疗可切除的局部晚期头颈部鳞状细胞癌（NeoRTPC02）：一项开放标签、单组、两阶段、II期临床试验的第一阶段结果Neoadjuvant low-dose radiotherapy, tislelizumab, combined with albumin-bound paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoRTPC02): The first-stage result from an open label, single-arm, two stage, phase II clinical trial（2023 ASCO：6078P）报告人：南方医科大学附属东莞医院肿瘤中心 刘志刚

5.    替雷利珠单抗联合化疗作为诱导治疗，随后进行放化疗或手术治疗局部晚期下咽鳞状细胞癌：一项单臂II期试验Tislelizumab plus chemotherapy as induction treatment followed by chemoradiotherapy or surgery in locally advanced hypopharyngeal squamous cell carcinoma: A single-arm, phase II trial（2023 ASCO：6087P）报告人：中国医学科学院附属肿瘤医院 桂琳

Session 2 头颈部鳞癌放疗进展
局晚期头颈部鳞癌放疗进展
1.         局部晚期头颈部肿瘤（LA HNSCC）同步v.s序贯帕博利珠单抗联合放化疗（CRT）的随机II期研究：4年结果和肿瘤免疫微环境分析A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) in locally advanced head and neck cancer (LA HNSCC): 4-year results and tumor-immune microenvironment analysis（2023 ESMO：856MO）

2.         将乏氧调节剂Nimorazole加入放疗的随机Ⅲ期试验（NIMRAD）：在应用基因标记确定的肿瘤微环境缺氧头颈部鳞状细胞癌中的疗效评估Randomised phase III trial of the hypoxia modifier nimorazole added to radiotherapy with benefit assessed in hypoxic head and neck cancers determined using a gene signature (NIMRAD)（2023 ASCO：6006）

3.       HPV阴性局部晚期头颈部鳞状细胞癌（HNSCC）接受纳武利尤单抗、紫杉醇和卡铂新辅助治疗后基于应答进行分层放化疗：DEPEND试验Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.（2023 ASCO：6007）

4.       在使用立体定向消融放疗（SABR）治疗有1-3个寡转移灶的头颈癌（HNSCC）患者中省略一线化疗，GORTEC 2014-04 “OMET”随机II期试验OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase 2 trial（2023 ESMO：853O）
 
Session 3 头颈肿瘤新疗法盘点
头颈肿瘤创新药物及新型治疗策略梳理
1.       SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & Neck Squamous Cell Carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy. （2023 ESMO：LBA46）一项IIa期SAKK 11/16试验：评估接受≥1线全身治疗后疾病进展的复发/转移性头颈鳞状细胞癌 (R/M HNSCC)患者接受MVX-ONCO-1（一种新型、同类首个基于细胞封装的免疫疗法）治疗的OS

2.       戈沙妥珠单抗（SG）治疗复发/难治性（R/R）晚期头颈部鳞状细胞癌（HNSCC）患者（pts）：II期TROPiCS-03篮子试验结果Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase 2 TROPiCS-03 basket trial（2023 ASCO：859MO ）

3.       一项II期研究评估tipifarnib在HRAS突变的复发性或转移性（R/M）头颈部鳞状细胞癌（HNSCC）中的作用（AIM-HN研究）A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study).（2023 ESMO：LBA47）

4.       双功能EGFR/TGFβ抑制剂BCA101联合帕博利珠单抗在复发、转移性头颈部鳞状细胞癌患者中的剂量扩展研究结果Dose expansion results of the bifunctional EGFR/TGFb inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.（2023 ASCO：6005）

5.       两项在复发性和转移性头颈部鳞状细胞癌（HNSCC）患者（pts）中开展的SI-B001（一种EGFR× HER3双特异性抗体）联合/不联合化疗的II期研究的结果Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC)（2023 ASCO：6037P）报告人：同济大学附属东方医院 薛丽琼

Session1：胃癌围手术期治疗
围术期化疗/辅助化疗模式探寻：RESOLVE研究5年生存数据更新（2023 ESMO LBA78）
——接受D2胃切除术的局部晚期胃或胃食管结合部腺癌患者围手术期或术后辅助奥沙利铂联合S-1与辅助奥沙利铂联合卡培他滨的总生存期：RESOLVE试验的更新分析

围术期免疫联合化疗模式探寻：MATTERHORN研究（2023 ESMO LBA73）
——度伐利尤单抗+FLOT治疗可切除胃和胃食管结合部癌的病理学完全缓解：全球3期MATTERHORN研究的中期结果

围术期免疫联合化疗模式探寻：KEYNOTE-585研究（2023 ESMO LBA74）
——帕博利珠单抗联合化疗对比安慰剂联合化疗作为局部进展期胃癌和胃食管结合部癌的新辅助和辅助治疗——全球III期KEYNOTE-585 研究

围术期免疫联合化疗模式探寻：特瑞普利单抗联合SOX或XELOX化疗 vs 单纯SOX或XELOX（2023 ASCO 4001）
——围手术期PD-1抗体特瑞普利单抗联合SOX或XELOX化疗 vs 单纯SOX或XELOX治疗局部晚期胃癌或食管胃结合部癌：一项前瞻性、随机、开放标签、II期试验结果

围术期免疫联合化疗及靶向治疗：DRAGON IV/CAP 05（2023 ESMO 1512MO）
——卡瑞利珠单抗联合阿帕替尼和化疗 vs 化疗围手术期治疗局部晚期可切除G/GEJ腺癌(DRAGON IV/CAP 05首次中期分析)

胃癌术后免疫联合化疗辅助治疗：ATTRACTION-5研究（2023 ASCO 4000）
——ATTRACTION-5研究：纳武利尤单抗联合化疗作为病理学Ⅲ期（pStage Ⅲ）胃或胃食管结合部（G/GEJ）肿瘤的术后辅助治疗

胃食管腺癌辅助免疫治疗：EORTC 1707 VESTIGE研究（2023 WCGIC O-6）
——术前化疗后手术切除的高复发风险（ypN+和/或 R1）、胃食管腺癌（GEA）患者接受辅助免疫治疗： 一项开放标签的随机对照Ⅱ期研究（EORTC 1707 VESTIGE）
 
Session2：晚期胃癌免疫治疗及靶向治疗进展
晚期一线
GEMSTONE-303研究PFS、OS最终分析（2023 ESMO LBA79）
——GEMSTONE-303: 舒格利单抗+化疗 vs 安慰剂+化疗一线治疗晚期胃或胃食管结合部腺癌(GC/GEJC)的III期研究的无进展生存期(PFS)和总生存期(OS)最终分析

RATIONALE-305研究最终分析结果（2023 ESMO LBA80）
——替雷利珠单抗+化疗 vs 安慰剂+化疗一线治疗晚期胃或胃食管结合部腺癌(GC/GEJC):RATIONALE-305研究的最终分析结果

KEYNOTE-859研究达到主要终点，在线发表（2023 Lancet Oncol、2023 ESMO Virtual Plenary）
帕博利珠单抗+化疗 vs 化疗一线治疗HER2阴性晚期胃癌 (KEYNOTE-859): 一项多中心、随机、双盲III期研究

CheckMate 649研究3年随访数据公布（2023 ASCO 291 oral）
——纳武利尤单抗联合化疗对比化疗一线治疗晚期GC/GEJC/EAC:checkMate 649研究3年随访数据

ORIENT-16研究最终OS结果（2023 AACR）
——信迪利单抗联合化疗 vs 安慰剂+化疗一线治疗不可切除G/GEJ癌: 随机、3期ORIENT-16研究最终OS结果

HER2+晚期胃癌：KEYNOTE-811的生存结果（2023 ESMO 1511O）
——帕博利珠单抗联合曲妥珠单抗和化疗一线治疗HER2+转移性胃或胃食管结合部(mG/GEJ)腺癌:来自III期、随机、双盲、安慰剂对照KEYNOTE-811研究的生存结果

MSI-H一线去化疗：NO LIMIT研究的初步结果（2023 ESMO 1513MO）
——纳武利尤单抗联合低剂量伊匹木单抗一线治疗MSI-H晚期胃或食管胃结合部癌患者的II期研究:NO LIMIT研究的初步结果(WJOG13320G/CA209-7W7)

CLDN18.2一线联合化疗：3期GLOW研究结果更新（2023 ESMO LBA81、2023 Nat Med期刊）
——III期GLOW研究的最新疗效和安全性结果：评估zolbetuximab+CAPOX一线治疗CLDN18.2+、HER2-、局部晚期(LA)不可切除或转移性胃或胃食管结合部(mG/GEJ)腺癌患者

CLDN18.2一线联合化疗：3期SPOTLIGHT研究结果更新（2023 ESMO LBA82、2023 Lancet期刊）
——III期SPOTLIGHT研究的最新疗效和安全性结果：评估zolbetuximab+mFOLFOX6一线治疗CLDN18.2+、HER2−、局部晚期(LA)不可切除或转移性胃或胃食管结合部(mG/GEJ)腺癌患者
 
晚期二线及以上治疗
DESTINY-Gastric02研究（2023 Lancet Oncol期刊）
——Trastuzumab deruxtecan用于含曲妥珠单抗方案治疗进展后的HER2阳性晚期胃癌或胃食管结合部癌患者：来自单臂2期研究的主要和最新分析

Session1：白血病研究进展
急性髓系白血病（AML）
根据风险细化的新兴疗法和治疗反应:
奎扎替尼联合诱导化疗为FLT3-ITD突变AML患者带来生存获益（QuANTUM-First phase 3 trial）：Erba HP, Montesinos P, Kim HJ, et al; QuANTUM-First Study group. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571-1583. doi:10.1016/S0140-6736(23)00464-6

Enasidenib vs.常规治疗晚期IDH2突变复发/难治性急性髓细胞白血病老年患者的随机3期试验。Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. Blood. 2023 Jan 12;141(2):156-167. doi: 10.1182/blood.2021014901.

中危急性髓系白血病患者的异基因造血细胞移植vs.标准巩固化疗的随机临床试验：Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2023 Apr 1;9(4):519-526.doi: 10.1001/jamaoncol.2022.7605.

DNA测序MRD指导疾病预后:
移植前FLT3/NPM1变异的持续存在预示着AML的不良结局：DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant JAMA.2023;329(9):745–755.doi:10.1001/jama.2023.1363 https://jamanetwork.com/journals/jama/article-abstract/2802059

中国好声音：
2023 ASH: 塞利尼索+维奈克拉+阿扎胞苷联合治疗新诊断Unfit AML的前瞻性研究: Li Yang, Fangli Chen, et al. Selinexor in Combination with Venetoclax and Azacitidine for Newly Diagnosed (ND) Unfit Acute Myeloid Leukemia (AML): A Multicenter, Open-Label Prospective Study. 2023ASH. Abs:55https://ash.confex.com/ash/2023/webprogram/Paper184581.htm

优化移植后维持治疗：索拉非尼在 FLT3-ITD 急性髓系白血病患者中的作用Prof Li Xuan, MD，Prof Yu Wang, MD，et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. The Lancet Haematology. DOI:https://doi.org/10.1016/S2352-3026(23)00117-5

中国学者探讨急性髓系白血病新亚型（RARG重排AML）的临床、MICM特征、治疗和结局：Hong-Hu Zhu, Ya-Zhen Qin, et al. A global study for acute myeloid leukemia with RARG rearrangement. Blood Adv (2023) 7 (13): 2972–2982.https://doi.org/10.1182/bloodadvances.2022008364
 
 
急性淋巴细胞白血病（ALL）
Car-T细胞疗法:
【NEJM】 全球首个碱基编辑通用型CAR7-T细胞治疗儿童T-ALL临床结果发布: Robert Chiesa, M.D., Christos Georgiadis, Ph.D., et al. Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia. June 14, 2023. NEJM.DOI: 10.1056/NEJMoa2300709

儿童 B 细胞急性淋巴细胞白血病联合应用 CD19 和 CD22 导向的嵌合抗原受体 T 细胞疗法： 单臂多中心 II 期试验：Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial. J Clin Oncol. 2023 Mar 20;41(9):1670-1683. doi: 10.1200/JCO.22.01214. Epub 2022 Nov 8.

ELIANA试验中Tisagenlecleucel治疗复发/难治性急性淋巴细胞白血病儿童和年轻成人患者的3年最新进展. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol. 2023 Mar 20;41(9):1664-1669. doi: 10.1200/JCO.22.00642. Epub 2022 Nov 18.

Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study. https://meetings.asco.org/abstracts-presentations/219864
 
免疫疗法之TKI联合单抗：
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023 Jan;10(1):e24-e34. doi: 10.1016/S2352-3026(22)00319-2. Epub 2022 Nov 16.
 
传统疗法的创新：
重组Erwinia天冬酰胺酶（JZP458）治疗急性淋巴细胞白血病：2/3 期 AALL1931 研究结果Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. Blood. 2023 Feb 16;141(7):704-712.doi: 10.1182/blood.2022016923.

Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial. J Clin Oncol.2023 Jan 10;41(2):343-353. doi: 10.1200/JCO.22.00767. Epub 2022 Sep 9.

Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial. DOI: 10.1200/JCO.23.00101 Journal of Clinical Oncology
 
中国好声音：
潘静主任团队CD19和CD22 CAR-T细胞序贯治疗R/R B-ALL最新研究结果发表于Lancet Oncology：Jing Pan, MD，Kaiting Tang, BS，et al. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. The Lancet Oncology. Published: October 17.

【2023 ICML中国之声】46例难治/复发小儿成熟B细胞淋巴瘤患儿的疗效分析--来自中国的多中心经验：Y. Zhang, S. Huang, et al. ANALYSIS TREATMENT OUTCOME OF 46 REFRACTORY/RELAPSED PEDIATRIC MATURE B CELL LYMPHOMA PATIENTS-MULTI-CENTER EXPERIENCE FROM CHINA. https://onlinelibrary.wiley.com/doi/10.1002/hon.3163_32

【2023 EHA中国之声】南方医院蔡梓红教授团队IKZF1缺失在CD19 CAR-T细胞治疗r/r B-ALL中的影响： Zihong Cai,Ting Zhang,et al. IMPACT OF IKZF1 DELETION IN RELAPSED AND/OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH CD19-CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY. IMPACT OF IKZF1 DELETION IN RELAPSED AND/OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH CD19-CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY.

【2023 EHA中国之声】潘静教授团队首次评估供体来源CD5 Car-T细胞治疗T-ALL的安全性与疗效: Jing Pan,  Yue Tan, et al. DONOR-DERIVED CD5 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. https://library.ehaweb.org/eha/2023/eha2023-congress/387816/jing.pan.donor derivedcd5cartcellsfor.tcell.acute.lymphoblastic.leukemia.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Ds116

【2023 EBMT中国好声音】唐晓文教授团队：CD38靶向CAR-T细胞治疗R/R AML的长期安全性和有效性: Xiaowen Tang, et al. OS20-05 LONG-TERM SAFETY AND EFFICACY OF CD38-TARGETED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: A SINGLE-ARM, OPEN-LABEL, PHASE 1-2 TRIAL https://ebmt2023.abstractserver.com/program/#/details/presentations/1796

【2023 EBMT中国好声音】黄河教授团队：抗CD7 CAR-T细胞治疗复发或难治性CD7+ AML的首次人体研究: Mingming Zhang, et al. OS20-07 HIGH SAFETY AND EFFICACY OF ANTI-CD7 CAR-T CELLS IN TREATING RELAPSED OR REFRACTORY CD7+ ACUTE MYELOID LEUKEMIA: FIRST-IN-HUMAN PHASE I STUDY.
https://ebmt2023.abstractserver.com/program/#/details/presentations/1809
 
 
慢性淋巴细胞白血病（CLL）
BTKi：
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2023 Jan 26;388(4):319-332. doi: 10.1056/NEJMoa2211582. Epub 2022 Dec 13.

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N Engl J Med.2023 Jul 6;389(1):33-44. doi: 10.1056/NEJMoa2300696.

一线治疗组合：
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med. 2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 May;24(5):535-552. doi: 10.1016/S1470-2045(23)00144-4.

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun. 2023 Apr 18;14(1):2147.
 
Car-T细胞疗法:
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 Aug 19;402(10402):641-654. doi: 10.1016/S0140-6736(23)01052-8. Epub 2023 Jun 6.
 
 
慢性粒细胞白血病（CML）
TKI:
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023 Mar;37(3):617-626.

生活质量：
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. Leukemia. 2023 May;37(5):1060-1067. doi: 10.1038/s41375-023-01888-y.

中国好声音：
【中国之声】陆军军医大学新桥医院张曦教授团队发现：Cx43修饰的骨髓基质细胞通过Ca2+依赖的缝隙连接细胞间通讯逆转了K562细胞的伊马替尼耐药性：Xiaoping Li, Yunshuo Xiao , Xiaoqi Wang, et al; Connexin 43-modified bone marrow stromal cells reverse the imatinib resistance of K562 cells via Ca2+-dependent gap junction intercellular communication;Chinese Medical Journal 2023;DOI: 10.1097/CM9.0000000000002554.
 
 
Session2：淋巴瘤研究进展
 
霍奇金淋巴瘤（HL）
HL的新药治疗进展:
Keynote-B68研究结果更新：全球性2期KEYNOTE-B68试验（NCT04875195）评估了帕博利珠单抗（400 mg，Q6W）治疗R/R cHL或R/R PMBCL患者（pts）的疗效和安全性（2023 ASH）Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper186800.html

替雷利珠单抗联合GemOx治疗复发/难治性经典型霍奇金淋巴瘤患者:多中心Ⅱ期临床试验Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial.DOI: 10.1111/bjh.17849

长期OS数据为维布妥昔单抗治疗霍奇金淋巴瘤提供依据Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma

维布妥昔单抗联合帕博利珠单抗治疗复发/难治霍奇金淋巴瘤：单中心回顾性研究Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysisdoi: 10.3390/cancers14040982.

PD-1单抗治疗复发难治经典霍奇金淋巴瘤具有长期生存获益Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma. doi: 10.1038/s41392-023-01600-7.
 
HL的新型诊疗手段进展
早期低危霍奇金淋巴瘤PET2驱动治疗：3期HD16研究5年随访结果Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. Leukemiadoi: 10.1038/s41375-023-02064-y.
 
中国好声音
真实世界中，应用PD-1抑制剂治疗中国复发/难治性霍奇金淋巴瘤患者的疗效及安全性Real-world experience of PD-1 inhibitors for relapsed and refractory Hodgkin lymphoma:A multicenter retrospective analysis of patients in China.Acta Haematol.DOI: 10.1159/000530323
 
BTK抑制剂治疗进展
BTK抑制剂泽布替尼联合CD20单抗奥妥珠单抗 (ZO) 方案方案VS O单药治疗复发/难治性（R/R)FL的疗效与安全性（2023 EHA）ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphomadoi: 10.1200/JCO.23.00775.
 
CD20/CD3双抗Epcoritamab相关治疗进展
Epcoritamab联合利妥昔单抗和来那度胺（R2）方案治疗高危滤泡性淋巴瘤的疗效（2023 ASCO）Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 statushttps://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.7506
 
ctDNA在FL治疗的预测价值
基线ctDNA可能预示着滤泡性淋巴瘤的治疗结果Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a prospective pilot study. doi:10.1158/1078-0432.CCR-22-1654

中国好声音
YY20394治疗复发和/或难治滤泡性淋巴瘤患者的单臂、开放、多中心II期临床试验（2023 EHA）The oral PI3Kδ inhibitor linperlisib for the treatment of relapsed and / or refractory follicular lymphoma: A phase 2, single - arm, open - label clinical trial.doi: 10.1158/1078-0432.CCR-22-2939.

特殊部位受累的FL临床治疗策略更新Clinical characteristics and outcomes of follicular lymphoma patients with extranodal involvement: analysis of a series of 1090 cases in China.doi: 10.1007/s12094-023-03081-0.
 
 
边缘区淋巴瘤（MZL）
BTK抑制剂治疗进展
3期SELENE研究：伊布替尼加入BR/R-CHOP方案治疗R/R FL/MZL患者并未显著改善PFS
Phase 3 SELENE Study: Ibrutinib Plus BR/R-CHOP in Previously Treated Patients with Follicular or Marginal Zone Lymphoma.doi: 10.1182/bloodadvances.2023010298.
 
临床诊疗、预后相关进展
一项多中心回顾性研究评估了诊断时循环淋巴瘤细胞对MZL患者预后的影响Impact of circulating lymphoma cells at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study.doi: 10.1182/bloodadvances.2023011288.

早期完全缓解作为结外边缘区淋巴瘤系统治疗的替代标志物Early Complete Response as Validated Surrogate Marker in Extranodal Marginal Zone Lymphoma Systemic Therapy.doi: 10.1182/blood.2023020984.
 
中国好声音
奥布替尼治疗复发/难治性边缘区淋巴瘤的2期研究结果Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.doi: 10.1002/ajh.27064.
 
套细胞淋巴瘤（MCL）
BTK抑制剂治疗进展
MCL一线免疫化疗后伊布替尼维持治疗的II期研究Ibrutinib Maintenance Following Frontline Treatment in Patients with Mantle Cell Lymphomadoi: 10.1182/bloodadvances.2023011271.
 
临床诊疗、预后相关进展
一项回顾性研究探讨了母细胞样和多形性变异型套细胞淋巴瘤的特征、治疗和预后Outcomes of Patients with Blastoid and Pleomorphic Variant Mantle Cell Lymphoma.doi: 10.1182/bloodadvances.2023010757.

DLBCL基于分子分型给予R-CHOP-X的Guidance-01 II 期随机研究结果Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial.doi: 10.1016/j.ccell.2023.09.004.

一线无化疗LR方案的9年随访结果Nine-year Follow-up of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphomadoi: 10.1182/bloodadvances.2023010606.
 
CAR-T细胞疗法
CAR-T联合伊布替尼治疗R/R MCL的2期TARMAC研究结果CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study.doi: 10.1182/blood.2023021306.

CAR-HEMATOTOX评分在CAR T治疗R/R MCL中的预后价值CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.doi: 10.1002/ajh.27056.
 
 
弥漫性大B细胞淋巴瘤（DLBCL）
CD19单抗治疗
Tafasitamab联合来那度胺治疗复发难治大B细胞淋巴瘤的178例回顾性研究Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes in a multicenter retrospective study doi: 10.1182/blood.2023021274.

CD19单抗Tafasitamab治疗R/R DLBCL的II期研究5年安全性和疗效afasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study.doi: 10.3324/haematol.2023.283480.
 
临床诊疗、预后相关进展
局限期原发骨DLBCL的当代预后：多中心回顾性研究Outcomes of limited-stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.doi: 10.3324/haematol.2023.283210.

骨骼受累DLBCL患者长期预后良好，PET/CT可用于缓解评估Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good long-term outcomesdoi: 10.3324/haematol.2022.282643.
 
CAR-T细胞疗法
CAR-T在LBCL一线和二线治疗中的作用演变Evolving Role of CAR T Cell Therapy in First‑ and Second‑Line Treatment of Large B Cell Lymphoma.doi: 10.1007/s11912-023-01466-6.

CAR-T治疗复发性/难治性 (r/r) LBCL伴肾功能下降的真实世界疗效和安全性Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function.doi: 10.1111/bjh.19152.

axi-cel治疗不适合自体移植LBCL的2期ALYCANTE研究结果Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation the phase 2 ALYCANTE trial.doi: 10.1038/s41591-023-02572-5.

中国好声音：
Glofitamab单药治疗多线治疗后的中国R/R DLBCL安全有效Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma.Haematologicadoi: 10.3324/haematol.2023.283802.
 
 
 
开放式主题：淋巴瘤科研进展与临床实践
淋巴瘤研究的新技术与方法
单细胞测序技术在淋巴瘤研究中的应用
蛋白质组学分析淋巴瘤细胞的新策略
淋巴瘤组织3D模型在药物筛选中的应用
多学科合作在淋巴瘤诊治中的作用
临床与实验室科研合作优势与挑战
医疗团队中不同专业合作的利弊与策略
独立研究机构与医疗机构合作的研究成果
淋巴瘤临床实践中的个体化治疗
基因检测在淋巴瘤治疗中的应用与争议
个体化药物治疗在淋巴瘤中的效果与开展
外周血淋巴细胞与淋巴瘤疗效评估的新进展
 
 
Session3：MDS 单药和联合治疗的更新
 
低风险MDS多种治疗方案的决策制订
Imetelstat在严重输血依赖（TD）非del(5q)低危骨髓增生异常肿瘤（LR-MDS），对ESA复发难治患者中的随机、双盲、安慰剂对照、3期研究的结果：https://meetings.asco.org/abstracts-presentations/219862

罗特西普一线治疗未使用促红细胞生成素，输血依赖的低风险MDS患者的疗效与安全性：首次发布3期COMMANDS研究结果：https://meetings.asco.org/abstracts-presentations/219861Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial：Lancet. 2023 Jul 29;402(10399):373-385.doi: 10.1016/S0140-6736(23)00874-7. Epub 2023 Jun 10.

来那度胺和艾曲波帕治疗低危或中危骨髓增生异常综合征：二期临床试验结果。Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial. Clin Cancer Res. 2023 Jan 4;29(1):60-66. doi: 10.1158/1078-0432.CCR-22-1457.
 
高风险MDS新型疗法进展：免疫治疗崭露头角
在新确诊的 60 岁或以上急性髓系白血病 (AML)、高危骨髓增生异常综合征 (MDS) 或慢性粒细胞白血病 (CMML) 患者中开展的 "新型疗法 "与阿扎胞苷的随机 II/III 期研究：阿扎胞苷和nivolumab vs.阿扎胞苷的比较报告：SWOG S1612：A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leuk Lymphoma 2023 Feb;64(2):473-477.doi: 10.1080/10428194.2022.2148212. Epub 2022 Dec 14.

Magrolimab联合阿扎胞苷治疗高风险骨髓增生异常综合征患者： Ib 期研究的最终结果：Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. J Clin Oncol. 2023 May 20;41(15):2815-2826. doi: 10.1200/JCO.22.01794. Epub 2023 Mar 8.
 
中国好声音：
浙大附一金洁教授团队：杰克替尼或可成为芦可替尼不耐受的骨髓纤维化患者治疗新选择：Zhang Y, Zhou H, Duan M, Gao S, He G, Jing H, Li J, Ma L, Zhu H, Chang C, Du X, Hong M, Li X, Liu Q, Wang W, Xu N, Yang H, Lu B, Yin H, Wu L, Suo S, Zhao Q, Xiao Z, Jin J. Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study. Am J Hematol. 2023 Oct;98(10):1588-1597. doi: 10.1002/ajh.27033. Epub 2023 Jul 20. PMID: 37470365.
 
Session4：MM领域研究进展
 
免疫治疗-单抗，双抗
Elotuzumab联合泊马度胺和地塞米松治疗复发性/难治性多发性骨髓瘤： ELOQUENT-3随机II期试验的最终总生存期分析: Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. J Clin Oncol. 2023 Jan 20;41(3):568-578. doi: 10.1200/JCO.21.02815.

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 Mar 10;41(8):1590-1599. doi: 10.1200/JCO.22.00940.

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Tria. J Clin Oncol. 2023 Mar 10;41(8):1600-1609. doi: 10.1200/JCO.21.02734.
 
Car-T细胞治疗
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614.

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023 Feb;29(2):422-429. doi: 10.1038/s41591-022-02182-7.

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379.

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023 Feb 20;41(6):1265-1274. doi: 10.1200/JCO.22.00842.
 
新一代蛋白酶体抑制剂
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023 May 9;13(1):72. doi: 10.1038/s41408-023-00797-8.

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma. DOI: 10.1200/JCO.23.01696 Journal of Clinical Oncology. Published online September 27, 2023.

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 Feb;24(2):139-150. doi: 10.1016/S1470-2045(22)00738-0.
 
中国好声音
安刚/邱录贵团队通过国内首个前瞻纵向血液病队列揭示骨髓瘤患者复发时小克隆17p缺失预后价值: Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma. Haematologica Early view Aug 3, 2023 https://doi.org/10.3324/haematol.2023.283533

胡豫及梅恒教授团队：双特异性 CS1-BCMA CAR-T 细胞对R/R MM具有临床活性. Chenggong Li, Jia Xu，et al. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia. 2023 Oct 17.doi: 10.1038/s41375-023-02065-x. Online ahead of print.

邱录贵教授团队：多发性骨髓瘤基于年龄变化的预后因素风险权重：Chenxing Du, Lingna Li, Huishou Fan, Xuehan Mao, Jiahui Liu, Yan Xu, Weiwei Sui, Shuhui Deng, Chengwen Li, Jiawei Zhao, Shuhua Yi, Mu Hao, Dehui Zou, Yaozhong Zhao, Lugui Qiu & Gang An (2023) The age-dependent changes in risk weights of the prognostic factors for multiple myeloma, Hematology, 28:1, 2258686, DOI: 10.1080/16078454.2023.2258686

诱导治疗后MRD阴性的MM患者可获益于自体造血干细胞移植：Liu J, Yan W, Fan H, Xu J, Li L, Du C, et al. Clinical benefit of autologous stem cell transplantation for multiple myeloma patients achieving undetectable minimal residual disease after induction treatment. Cancer Research Communications. 2023.